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When my kids were young I played a game with them. 
I'd give each of them a stick. One for each of 'em, and I'd tell them to break it. 
They'd do that easy. 
Then I'd tell them to make one bundle of all the sticks and try to break that. 
A course they couldn't. 
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1. Introduction
The use of nanotechnology in the field of medicine emerged in the late 1970's when  
first publications described the application of nanoparticles as drug carrier systems. 
Groups around Jörg Kreuter[1][2][3] and Patrick Couvreur[4][5][6][7] laid the foundation for a 
rapidly growing field. In these first publications manufacturing, administration, tissue 
distribution,  pharmacokinetics  and  toxicity  of  poly(alkylacryl)  nanoparticles  were 
investigated. With the turn of the millennium the number of publications [8] started to 
grow exponentially to a total of about 25,000 in 2009 (fig. 1). This reflects also the 
widened use in other fields like physics, biology, engineering, and robotics. 
One of the most prominent properties is the introduction of functionalized surfaces 
with  large  area-volume ratios.  Hence,  the  variety  of  materials,  compositions  and 
structures  of  used  nanomaterials  increases  considerably.  What  they  all  have  in 
common  is  that  nanoparticles  are  used  to  increase  the  designated  action  on  a 
designated site with less effort and less adverse effects [9]. This applies for instance 
for use of nanoparticles as antitumor drug carriers, where the drug concentration and 
activity  within  a tumor  are increased while  the  systemic  concentration  and,  thus, 
adverse  effects  are  reduced.  An  other  example  is  the  imaging  and  targeting  of 
vascular smooth muscle cells in stents for detection and therapy of restenosis [10]. 
Furthermore, nanoparticles enable the use of poorly water soluble compounds which 
allows the development of a wide range of potent drugs.
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Figure 1: Number of publications (PubMed, search term "nanoparticle")[8]
1.1. Aim of this work
Polymeric  nanoparticles  are  a  promising  tool  for  controlled  and  targeted  drug 
administration and diagnostics. One of the most challenging goals is to overcome the 
blood-brain barrier facilitating the treatment of neurological disorders like Alzheimer's 
disease,  Parkinson's  disease  or  brain  tumors.  Within  the  last  decade  animal 
treatment  studies showed superiority  of  nanoparticle  bound drugs over  traditional 
therapies, but also many studies failed.
Less is known about the mechanisms how these particles are distributed with the 
blood stream, how they penetrate the blood-brain barrier or how they are degraded 
within the targeted tissue. To enlighten these questions fluorescent polymeric core-
shell nanoparticles are used in this work. The targeting of disease-based alterations 
of brain tissue will be proved by using the fluorescent model drug Thioflavin T in an 
transgenic mouse model displaying Alzheimer-like pathology. Therefore, the drug is 
encapsulated  within  a  degradable  nanoparticle  shell,  usually  made  of  poly(butyl  
cyanoacrylate). The penetration of the blood-brain barrier would be proved by stable 
nanoparticle cores which remain at the nanoparticle degradation site.
In this work, animal experiments were intended to show the ability of nanoparticles to 
overcome the blood-brain barrier. Methods and materials should be described, which 
allow to follow the mechanisms of this process. Furthermore, the experiments were 
also focused on the elucidation of possible side effects.  Besides the brain,  other 
organs of treated animals were analyzed for nanoparticle uptake; the influence of 
polymeric nanomaterial on blood coagulation was studied.
The  in  vivo behavior  of  nanoparticles  is  determined by biochemical  and physical 
properties of the used materials. Particle size may influence the uptake efficiency,  
surface  alterations  affect  targeting  and  biocompatibility,  whereas  degradation 
determines the drug release. These properties have to be investigated using in vitro 
techniques like absorbance measurements, light or neutron scattering. In addition, 
the usefulness of physical and biochemical methods for the investigation of polymeric 
nanoparticle properties had to be tested.  In vitro methods may be helpful  for  the 
better understanding of nanoparticle properties. Furthermore, these techniques may 
reduce the number of animal experiments which are needed for the development of  
these seminal drug carriers.
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1.2. Composition and chemical properties of nanoparticles
Nanoparticles  might  be  composed  of  organic,  inorganic  or  biological  materials: 
methoxy poly(ethylene glycol) /  poly(ε-caprolactone), poly(alkyl  cyanoacrylate)[11][12], 
poly(lactic-co-glycolic acid)[13][14],  cetyl  alcohol/polysorbate[15],  hydrogels[16],  gold[17][18], 
magnetic  iron  oxide[19],  solid  lipid  formulations[20][21],  chitosan[22][23],  gelatin[24] or 
albumin[25].  Dendrimers  are  branched  polymeric  particles  where  the  drug  is 
polymerized  itself[26].  The  presented  work  is  focused  on  nanoparticles  based  on 
polymeric materials.
1.2.1. Polymeric nanoparticles
Polymeric  nanoparticles  are  used  as  preferred  carriers  for  nanomaterial  drug 
delivery. Most of these particles are biodegradable, biocompatible and made of easy 
available  compounds  like  gelatins[27],  chitosan[28],  polylactic  acid  or  poly(lactic-co-
glycolic  acid)  copolymer[29],  poly(methyl  methacrylate),  poly(alkyl  cyanoacrylate) [30] 
and  poly(butyl  cyanoacrylate)[31].  By  adding  copolymers  it  is  possible  to  achieve 
specifically requested properties like surface charges[32] or introducing binding sites 
for ligands (fig. 2). Furthermore, these copolymers, the applied monomers as well as 
particle  size determine the  stability  and the release of  drugs during degradation. 
Polymeric  nanoparticles  exhibit  a  high  potential  for  surface  modifications  by 
adsorption as well as chemical bonding of ligands. Surface modifications determine 
stability, body distribution, and degradation of nanoparticles[3]. 
There are different ways to assign substances like drugs or dyes to nanoparticles by 
adsorption, covalent binding or inclusion[33]. 
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Figure 2: Different surface properties of nanoparticles[32]
1.2.2. Synthesis of spherical polymeric nanoparticles
Polymeric  nanoparticles  are  synthesized  by  emulsion  polymerization [34][35][36][37]. 
Thereby,  the monomer is emulsified in a solution of surfactant and water  forming 
surfactant stabilized droplets of the immiscible monomer in water. An excess of the 
surfactant leads to micelle formation within the solution, small amounts of monomer 
diffuse  through  the  water  into  the  micelle.  A  water-soluble  initiator  reacts  with 
monomers  within  micelles  or  single  solved  monomers  which  diffuse  to  micelles 
(radical  polymerization).  The polymerization stops if  the monomer runs short  or a 
second  radical  interferes  with  the  reaction.  Due  to  the  reduced  concentration  of 
dissolved  monomers,  monomer  molecules  from  the  large  droplets  pass  into  the 
aqueous phase and into the micelles, the polymerization reaction starts over and 
over  by  remaining  radicals  until  the  amount  of  unbound  monomers  is  used  up. 
Nanoparticle cores of polystyrene are stabilized against coagulation by the surfactant 
as well as negatively charged terminal sulfate groups[38] and are routinely purified by 
ultracentrifugation  and  dialysis.  The  resulting  dispersion  is  also  called  colloidal 
dispersion or colloid.
The anionic polymerization of alkyl-cyanoacrylates is catalyzed by low concentrations 
of hydroxide ions (fig. 6). Due to the self-ionization of water the reaction is performed 
at  pH 2[40].  During  the  polymerization  the  resulting  sparingly  soluble  poly(butyl 
cyanoacrylate) (PBCA) is preferentially bound on the surface of the polystyrene core 
by hydrophobic interactions. The elongation of the polymer backbone is stopped by 
protons.  Particle  size  is  determined  by  temperature,  pH  value,  monomer 
concentration and added stabilizers[41]. PBCA is a uncharged polymer with tendency 
to coagulation, which can be avoided by the use of amphiphilic block copolymers like 
Poloxamer 188[42], composed of a hydrophobic chain of poly(propylene oxide) flanked 
by two hydrophilic chains of poly(ethylene oxide). The core-shell nanoparticles are 
purified by ultracentrifugation and dialysis.
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Figure 3: Radical polymerization for synthesis of poly(alkyl cyanoacrylates)[39]
After adding Thioflavin T or thioflavin S as model drugs to the reaction solution, these 
compounds were embedded within the polymeric spheres or absorbed to the surface. 
This  principle  was  also  shown  for  loperamide[43] or  doxorubicin[44].  The  dye 
rhodamine B  was  covalently  bound  to  epoxypropylmethacrylate  and  added  as  a 
reactant  to  polymerization  of  styrene  to  achieve  intense  red  fluorescent  particle 
cores. 
The synthesis  of  nanoparticles consisting of epoxypropylmethacrylate,  methacrylic 
acid or hydroxyethylmethacrylate was carried out as a radical polymerization initiated 
by potassium peroxidisulfate.
1.2.3. Chemical degradation
Polystyrene  is  resistant  against  aliphatic  alcohols  and alkalies.  Furthermore,  it  is  
slightly affected by strong as well  as weak acids. Polystyrene is unstable against 
organic and/or non-polar solvents (aldehydes, esters, ethers, ketones, aliphatic and 
aromatic  hydrocarbons)  and  oxidizing  agents.  Poly(alkyl  cyanoacrylates)  degrade 
slowly by a reversed KNOEVENAGEL reaction in the presence of distilled water; released 
substances are toxic formaldehyde and irritant cyanoacetic acid (fig.4). The reaction 
is catalyzed by hydroxide ions, the reaction rate depends on the pH of the solvent 
and the chain length of the side chain[39] as well as specific surface, particle size and 
polymer  molecular  weight[45].  While  poly(methyl  cyanoacrylate)  releases  large 
amounts,  poly(butyl  cyanoacrylate)  delivers  significantly  less  toxins.  Furthermore, 
poly(octyl  cyanoacrylate)  nanoparticles,  but  not  poly(octyl  cyanoacrylate-co-butyl  
cyanoacrylate)  nanoparticles  show lower  formaldehyde-mediated  cytotoxicity  then 
poly(butyl cyanoacrylate) nanoparticles[46]. On the other hand, some of the released 
formaldehyde may be neutralized by binding to the C-H-acidic end of the polymer  
chain[47].
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A second degradation reaction is the hydroxide-mediated ester hydrolysis of the side 
chain resulting in the release of  n-butanol [48].  This  reaction is strongly favored by 
esterase-mediated  enzymatic  degradation.  Poly(alkyl  cyanoacrylates)  (PACA)  are 
stable against organic and non-polar solvents as well  as acids. The resistance to 
acids  allows  a  oral  application  of  PACA  nanoparticles  whereas  in  the  basic 
environment of the intestine the nanoparticles are degraded resulting in the release 
of the drug. 
Nanoparticles which consist of poly(methyl  methacrylate) are stable against acids, 
basics, gasoline and oil, but sensitive against alcohols, acetone and benzene which 
form cracks.
1.3. Biochemical properties of nanoparticles
Nanoparticles,  entering  the  blood  stream,  encounter  a  complex  environment  of 
plasma proteins and immune cells.  Monocytes,  platelets,  leukocytes and dendritic 
cells may incorporate nanomaterials,  as well  as resident phagocytes,  like Kupffer 
cells in liver, dendritic cells in lymph nodes and macrophages and B cells in spleen. 
This uptake occurs through different pathways and is accompanied by the adsorption 
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Figure 4: Hydroxide-catalyzed degradation of poly(alkyl cyanoacrylates)[39]
of plasma proteins (opsonization)[49]. These processes influence the distribution of the 
nanoparticles in the body as well  as the release of the bound drugs and, hence,  
unwanted and unexpected adverse effects may occur (see chapter 1.4.5).
One of the commonly used surface modifications is coating or covalent linking of 
biologically inert poly(ethylene glycol) onto the nanoparticle surface [50][51] which leads 
to  reduced  protein  binding[52],  cell  adhesion[53], immunogenicity  and  limited 
phagocytosis by the reticuloendothelial system [54]. Furthermore, it is easy to introduce 
biological markers to determine cell or organ specificity. For instance, for targeting of  
the  blood-brain  barrier  of  nanoparticles  are  coated  with  apolipoprotein E[55] which 
leads to receptor-mediated endocytosis[56] through the blood-brain barrier mimicking 
the uptake of low density lipoprotein[57].
1.3.1. Enzymatic degradation
Polystyrene nanoparticles are not biodegradable [58]. Similarly, particles consisting of 
poly(methyl  methacrylate)  are  stable  and  remain  undegraded  for  months  after 
subcutaneous application[59].
PBCA nanoparticles are biodegradable due to the enzyme-catalyzed cleavage of the 
butyl side chain (fig. 5). This process is catalyzed by unspecific esterases and results 
in  the  release  of  a  water  soluble  poly(cyano  carbonic  acid)[60].  The  enzymatic 
degradation  is  also  shown  by  tissue  homogenates  of  various  tissues [61] or  liver 
microsomes[48].  The  biodegradation  of  poly(butyl  cyanoacrylate)  nanoparticles 
depends  on  pH,  ionic  strength,  temperature,  surface  modifications,  particle  and 
enzyme  concentrations[61][62] and  can  be  monitored  using  photometry  (see 
chapter 1.5.2.1.  ).  Furthermore, the reaction rate is controlled by the length of the 
alkyl side chain[63][64].
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1.3.2. Release of drugs
The  release  of  drugs  primarily  depends  on  the  kind  of  interaction  between 
nanoparticles and drugs. A substance adsorbed at the particle surface pass into the 
environment depending from its solubility.  Due to the large contact area between 
particle and surrounding solvent a burst release of the drug occurs. This type of drug 
delivery  may  be  helpful  in  topical  application[65] or  in  case  of  unstable  or  hardly 
soluble drugs[11][66]. 
If the drug is embedded within the polymer without covalent binding, it is released by 
desorption during the degradation of the nanoparticle.  Beside the aforementioned 
applications these nanoparticles can be used for the targeting of organs or tissues, 
for a considerable longer release durability in chronic diseases or vaccination [67].
In some cases the drug is bound covalently to the polymer. This may occur if the 
polymerization affects the drug or  vice versa. Furthermore, it might be a method to 
improve the drug concentration in the particle. After application  in vivo the drug is 
released by unspecific reactions, typically enzyme-catalyzed hydrolysis.
In the cases of embedded or covalently bound drugs, the kinetic of the drug release 
can be determined by nanoparticle composition[64].
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Figure 5: Degradation of poly(butyl cyanoacrylate)[48]
1.4. The use of drug-loaded nanoparticles in medicine
At the beginning of year 2006 about 130 nano-based drugs and delivery systems had 
entered preclinical,  clinical  or  commercial  development[68].  To  improve therapeutic 
options there is a need to deliver therapeutic agents in such a way that most drug 
molecules will  selectively reach the desired targets at optimal drug concentrations 
and with minimal collateral damage[69]. Drug-loaded nanoparticles are promising tools 
to achieve increased target selectivity and, therefore, reduce side effects.
One of the major fields in nanomedicine is the delivery of chemotherapeutic agents to 
cancer cells[70][71]. These drugs are known for a wide variety of strong adverse effects 
and there is a need for further improvements. Affected cancer cells express disease-
specific  molecules  like  receptors,  proteases  and  adhesion  molecules [69].  These 
molecules are different from their unaffected counterparts and, therefore, a unique 
target. Nanoparticles expressing specific antibodies or adhesion molecules are able 
to bind such targets and release the embedded drug close to it. A wide variety of  
cancer types are another challenge for the development of therapeutic agents.
Table 1: Nanoparticle classes, materials and applications in the field of medicine[72]
An other promising field is the application of nanoparticles in gene therapy [73]. The 












Branched polymers Drug delivery
Fullerenes Carbon based carriers Photodynamics
Drug delivery




Ferrofluids (Ultrasmall) superparamagnetic Imaging
iron oxide nanoparticles (Magnetic resonance imaging)
Quantum dots Cd/Zn-selenides Imaging
In vitro diagnostics
Various Silica-nanoparticles Gene delivery
Mixtures of above
permeation  for  cellular  uptake  is  excluded  due  to  its  size  and  negative  charge. 
Fundamental problems associated with  high effective viral  vector systems open a 
field  for  non-viral  carriers  with  lower  efficacy  but  superior  usability [74].  Attractive 
targets are epithelial surfaces of lung, gastrointestinal tract, blood vessels, muscles 
and skin[75]. In addition, tumor cells are possible targets[76].
Furthermore, nanoparticles enable oral[77], nasal[76] and topical application[78] as well 
as  ocular  drug  delivery[79].  Due  to  their  prolonged  stability  nanoparticles  are  a 
promising carrier for vaccines[80] or adjuvants[81]. 
Besides the therapeutic use, nanoparticles serve as tools for clinical diagnostics [82][83] 
and for basic research[84].
1.4.1. The blood-brain barrier
The first description of blood-brain barrier effects was given by Paul Ehrlich in 1885 
who  observed  that  after  injection  of  water  soluble  acidic  dyes  all  organs  of  the 
experimental animal were colored except the brain and the spinal cord. Since some 
dyes like Methylene blue[86][87] stain brain tissues he misinterpreted his findings as 
reduced affinity. One of Ehrlich's students, Edwin Goldmann, injected the dye directly 
into the spinal fluid of brain and found the brain dyed but not the rest of the body. In 
1921  Lina  Stern  proposed  the  concept  of  the  blood-brain  barrier  (then  termed 
hemato-encephalic barrier) but it was not 
until  the  1960's,  when  the  newly 
introduced scanning electron microscope 
helped to proof this concept.
In  the  brain  more  then  100  billion 
capillaries form a very dense network with 
a  total  length  of  about  600  km  and  an 
estimated surface area of 12–20 m2. The 
blood-brain barrier regulates brain uptake 
and release of substances[88].
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Figure 6: Cross section of the blood-brain barrier[85]
1.4.1.1. Endothelial cells
In  contrast  to  peripheral  blood  vessels,  endothelial  cells  of  the  central  nervous 
system form a tight vessel wall which restricts diffusion of microscopic objects and 
larger hydrophilic  molecules[85].  This barrier  is closed by a dense network of tight 
junctions (fig. 6/7) which link neighboring endothelial cells and prevent passive influx 
of most substances except very small, lipophilic molecules [90]. The blood-brain barrier 
exhibits a high permeability for water [91], mediated through aquaporins[92]. Compared 
to  peripheral  endothelium  pinocytosis,  a  process  of  unspecific  uptake  of  solved 
substances,  is  significantly  diminished  in  the  blood-brain  barrier [93].  On  the  other 
hand,  facilitated  diffusion,  which  allows  concentration  gradient  driven  specific 
transport for molecules like glucose, amino acids or short monocarboxylic acids, is a 
prominent uptake mechanism[94]. The brain, comprising only about 2% of the whole 
body  tissue  requires  about  20%  of  the 
whole energy[95]. Therefore, the cells of the 
endothelium contain  about  5  times  more 
mitochondria  then  peripheral  endothelial 
cells[96]. A significant part of the energy is 
used  for  active  receptor-mediated  uptake 
of molecules as well as receptor-mediated 
transcytosis. The former controls the influx 
of  required  molecules  like  hormones and 
the  efflux  of  hormones  or  degradation 
products, some of them are stereoselective 
transporters[97]. Among the highly important 
efflux receptors is the group of multi-drug 
resistance  proteins,  enabling  endothelial 
cells  to  remove  potent  threatening 
substances and so most drugs too[98].
Besides  physical  barriers,  drug-metabolizing  enzymes  at  the  blood-endothelium 
interface  provide  an  additional  enzymatic  barrier.  These  include  the  cytochrome 
P450  hemoproteins,  several  cytochrome  P450-dependent  monooxygenases, 
NADPH-cytochrome  P450  reductases,  UDP-glucuronosyltransferases,  alkaline 
phosphatases, glutathione peroxidases, and epoxide hydrolases[99][100][101][102].
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Figure  7:  Tight  junctions  of  the  blood-brain 
barrier (Freeze fracture morphology from rat)[89]
1.4.1.2. Basal lamina, astrocytes, pericytes
The basal lamina is an about 45 nm thin layer of extracellular matrix, surrounding 
epithelial  cells.  Their  components  are 
produced  by  the  cells  itself  and  are 
mainly  of  collagen  type IV,  heparan 
sulfate proteoglycans,  laminin and other 
extracellular matrix proteins[93]. 
Astrocytes are frequently star-shaped macroglial cells. They play an important role in 
the development,  maintenance and repair of brain tissue and signaling [104][105].  The 
endothelial  cells  of  the  blood-brain  barrier  are  encircled  by  astrocyte  end-feet. 
Contrary to the former opinion, they are not a part of the blood-brain barrier but it has 
been shown that  astrocytes  induce the formation of the tightened endothelial  cell  
network[106][107].
About 20% from the outer endothelium of the cerebral capillaries are covered with 
pericytes  which  fulfill  three  functions  within  the  blood-brain  barrier:  contractility,  
regulation of the endothelial cell activity and macrophage activity[108].
1.4.1.3. Crossing the blood-brain barrier
Crossing  the  blood-brain  barrier  is  one  of  the  most  important  topics  in  the 
development  of  drugs  targeting  the  brain[109].  Nanoparticles,  liposomes and  other 
polymeric colloids are considered as effective carriers for drugs to be transported into 
the  brain[110][111][112].  Positive  results  were  achieved  with  doxorubicin-containing 
nanoparticles  which  diminished  glioblastomas  with  higher  efficiency  than  free 
drugs[113].  Such  cancer  therapies  predominantly  based  on  drug-loaded  PBCA 
nanoparticles[9] which  were  shown  to  undergo  enzymatic  biodegradation  both  in  
vitro[63] and in vivo[114][115]. Core-shell nanoparticles provide further advances as they 
are composed of a hardly degradable PS core and a PBCA shell allowing a ‘burst 
release’  of  encapsulated  drugs[116].  Furthermore,  nanoparticles  coated  with 
polysorbate 80 and apolipoprotein E displayed an improved brain targeting[117][12].
Mechanisms of nanoparticle uptake by the blood-brain barrier is not enlightened until  
today. The presumably most promising approach is based on the increased transport  
after surface modification with apolipoprotein E[118] or an ApoE dipeptide which was 
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Figure 8: Basal lamina[103]
found to bound with high affinity to the receptor [119]. ApoE is found in chylomicrons, 
large  lipoprotein  particles,  and  regulates  the  uptake  into  cells  through  specific 
recognition by low density lipoprotein (LDL) receptors [120]. LDL receptors have been 
detected in the brain[121][122] and even more prominent in the liver which is responsible 
for LDL catabolism. Nevertheless, until now there is no proof, that intact polymeric 
nanoparticles - also if coated with polysorbate 80 and apolipoprotein E - crossed an 
intact blood-brain barrier. It is suspected, that the particles or their (toxic) degradation 
products may cross the blood-brain barrier after its disruption[123][124]. One goal of this 
work was an approach to demonstrate the uptake of nanoparticles into the brain in  
vivo and directly (see chapter 1.5.7.  ).  The study was performed using transgenic 
mice, which express mutated human amyloid  β (Aβ). Degeneration products of this 
protein  aggregate  to  insoluble  amyloid  plaques,  a  major  hallmark  of  Alzheimer's 
disease.  These aggregates  are  a  promising  target  for  drugs as  well  as  a  useful 
readout  for  successful  blood-brain  barrier  penetration.  Nanoparticles  were 
administered  intravenously,  intracerebroventricularly  and  intrahippocampally  to 
observe nanoparticle distribution within the body, targeting of the blood-brain barrier 
as well as of amyloid β.
1.4.2. Alzheimer’s Disease
Alzheimer's  disease (AD)  is  the  most  common neurodegenerative  disorder  of  an 
aging  society.  Major  symptoms  are  progressive  memory  impairment,  disordered 
cognitive function,  altered behavior,  delusions,  and loss of  social  appropriateness 
and a progressive decline in language function [125]. There are two different forms of 
the disease, the “juvenile” form with an onset before the age of 65 and a “senile” 
form, which occurs in patients above this age. The first one is often associated with 
defined genetic mutations whereas the latter seems to be multi-causal. Currently, the 
diagnosis of Alzheimer's disease can only made by post mortem examination of its 
major  histopathological  hallmarks  which  are  are  neurofibrillary  tangles [126] and 
amyloid  plaques[127].  Furthermore,  Alzheimer's  disease  is  associated  with  loss  of 
synapses[128] and neurons[129] and cholinergic depletion[130] but there is still no unitary 
theory  that  can  account  for  all  the  clinical  and  neuropathological  features [131]. 
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Moreover, it is not clear whether neurofibrillary tangles acting neuroprotective and/or 
pathogenic and whether amyloid plaques are cause or result of the disease.
Intracellular neurofibrillary tangles (NFT) are formed of insoluble hyperphosphoryl-
ated protein tau. The age-dependent tau hyperphosphorylation can be found in most 
individuals above an age of 60 and is strongly increased in patients with AD [132]. In 
early stages, the pathology emerges in the low limbic system, such as entorhinal 
cortex, hippocampus and the nucleus basalis of Meynert. Later on it expands to the 
high limbic system and finally tau pathology is affecting the neocortex [131]. 
In  its  less  phosphorylated  form  tau  stabilizes  the  microtubules  of  axonal 
cytoskeleton[133]. The loss of its normal function leads to a breakdown of the axonal 
transport  which results  in  a loss of  synaptic  function of  the affected neuron.  The 
cause for the hyperphosphorylation of tau is still unknown, but a regulated imbalance 
of phosphorylation and dephosphorylation was observed in hibernating animals [134].
Amyloid plaques contain insoluble fibrils of amyloid  β and accumulate in the extra-
cellular space. Besides various Aβ peptides these very inhomogeneous aggregates 
contain different substances like apolipoprotein E (ApoE) or heparan sulfate proteo-
glycans. Aβ results from the cleavage of the amyloid precursor protein (APP) by the 
enzymes γ-secretase and β-secretase, also known as β-amyloid cleaving enzyme[135]. 
Mutated presenilin subunit of  γ-secretase and APP mutations cause an abnormal 
production of amyloid β with a length of 42 or 43 amino acids (Aβ42 or Aβ43). These 
proteins tend to aggregation due to their high hydrophobicity [125], mutations in ApoE 
lead  to  a  protein  which  can  promote  Aβ  aggregation [136].  Furthermore,  amyloid 
plaques vary in their predominant vascular or parenchymal localization.
The role of Aβ plaques in the progression of AD was contested within the last years. 
A  clinical  study  with  vaccination  against  Aβ  showed  no  benefits  for  the  treated 
patients despite a significant reduction of amyloid load in patients [137] in contrast to 
studies in animals[138][139].  Recently,  it  was shown that the inhibition of γ-secretase 
and,  therefore,  amyloid  secretion,  worsened  the  disease in  a  phase III  study [140]. 
However, in this study a significant reduction of amyloid plaques was observed. 
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1.4.3. Thioflavin T and thioflavin S as model drugs for targeting of β-amyloid 
through the blood-brain barrier
Fibrillar  Aβ is bound by several dyes such as thioflavins which allow histochemical  
detection of pathological aggregated Aβ. Thioflavin T (also Basic Yellow 1, IUPAC: 4-
(3,6-dimethyl-1,3-benzothiazol-3-ium-2-yl)-N,N-dimethylaniline  chloride)  is  obtained 
by  the  methylation  of  dehydrothiotoluidine  with  methanol  in  the  presence  of 
hydrochloric  acid.  In  aqueous solution,  thioflavin  T exhibits  only  low fluorescence 
intensity (excitation 350 nm, emission 440 nm) and forms micelles above 4µM[141]. 
Thioflavin  T binds to  β-sheet  structures  of 
amyloid  oligomers.  Three  different  binding 
sites  have  been  revealed,  two  within  the 
grooves on β-sheet surface and one at the 
end  of  the  β-sheet[142].  While  binding  to 
aggregated β-amyloid, thioflavin T undergoes a significant red shift in its emission 
spectrum (excitation 440 nm, emission 490 nm). Additionally, the intensity increases 
several  orders  of  magnitudes[141][143].  After  intravenous injection  thioflavin  T shows 
weakly labeled vascular amyloid deposits but it is not able to pass the blood-brain 
barrier  to  label  parenchymal  amyloid[144].  Therefore,  only  if  bound  to  a  carrier, 
thioflavin T will be able to penetrate the blood-brain barrier and to target β-amyloid.
Thioflavin S is used as a dye to visualize β-amyloid containing plaques. It is a mixture 
of  as  many  as  six  compounds  that  results  from  the  methylation  of 
dehydrothiotoluidine. Thioflavin S also binds 
to  amyloid  fibrils[145][146] and gives  a spectral 
shift upon binding. Due to its high background 
fluorescence  it  appears  not  suitable  for  the 
quantification of fibril solutions.
The uncharged 4-(6-methyl-1,3-benzothiazol-3-ium-2-yl)-N,N-dimethylaniline (BTA-2) 
is a hardly water  soluble derivative of thioflavin T.  Due to its lipophilic  properties 
BTA-2 is able to cross the blood-brain barrier and then targeting fibrillar β-amyloid[146]. 
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Figure 10: Thioflavin S R1−3=H orCH 3
Figure 9: Chemical structure of Thioflavin T
1.4.4. Animal models
Until now there is no suitable general animal model for Alzheimer’s disease. On the 
one hand, classical laboratory animals, like mice or rats, only express an amyloid 
precursor  protein  variant,  which  is  degraded  to  exclusively  non-aggregating 
β-amyloid peptides not forming any plaque[147]. On the other hand, there are several 
animal species which develop plaques in higher age, e.g. rhesus monkey, baboon,  
guanaco,  reindeer  or  bison[148],  but  these  animals  are  not  suited  for  animal 
experiments also due to late onset of the phenotype. The most promising option is  
the use of transgenic animals; the expression of human amyloid precursor protein in 
species like  mice allows  to  study amyloidogenesis in  numerous animals  within  a 
defined time frame[149][150].
In the presented work two slightly different strains of animals were investigated. The 
APPswe/PS1(A246E)[151] double transgenic mice and the APPswe/PS1dE9[152] double 
transgenic mice express amyloid precursor protein as well as presenilin-1 variants 
which lead to an accelerated Aβ deposition in brain. These mice show typical signs of 
progressive memory impairment dependent on the amount of insoluble (aggregated) 
Aβ42 within the hippocampus[153].
1.4.5. Biological response and adverse effects
The wide variety of materials and applications of nanoparticles correlates with a wide 
variety of possible adverse effects. Different compounds of the nanoparticles as well  
as  their  degradation  products  may be  toxic  or  may  accumulate  within  the  body, 
organs or  cells.  These effects will  be also influenced by the way of  nanoparticle 
administration  (see fig.  11)[154].  Nanoparticles  display  a large surface which  allow 
interaction with blood or tissues. The most prominent protection systems, immune 
response and coagulation system, are influenced by xeno-materials and surfaces.
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1.4.5.1. Toxicity
Several  studies regarding nanoparticles and toxicity are focused on the action of  
unintentional  nanomaterial  uptake,  mainly  through  the  respiratory  system.  This 
includes air pollution from combustion products, fumes and particulate matter which 
are  known  to  cause  diseases  of  the  respiratory  tract  including  inflammation  and 
cancer[154]. Such diseases might be initiated by the uncontrolled nanomaterial uptake 
in phagocytes which cause activation of the immune system and alterations of cells,  
proteins and genetic material induced by free radicals[155]. Furthermore, air pollution is 
an  important  reason  for  cardiovascular  diseases[156].  The  rapid  increase  of 
nanomaterial  application  may also  lead to  an  enhanced percutaneous  or  peroral 
uptake. This leads to irritation, inflammation and alterations of the gastrointestinal 
tract and the skin. 
On the  other  hand,  nanoparticles are useful  as  carriers for  toxic  substances like 
chemotherapeutic  agents  in  cancer  therapy.  The  bound  agent  shows  lower  side 
effects and higher efficiency in therapy[70][25][44][157]. However, the the lower toxicity of 
the bound agent may cover toxicity which is introduced by using nanoparticles [72]. 
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Figure 11: Uptake, distribution and excretion of nanoparticles[154] (CNS – central nervous 
system, PNS – peripheral nervous system, GI gastrointestinal) 
Furthermore,  these  studies  were  not  designed  to  reveal  side  effects  induced  by 
nanoparticles. The toxicity of nanoparticles is induced by the particle itself but also by 
particle degradation products[158]. The degradation of PBCA nanoparticles used in this 
work releases n-butanol, which is known to alter cell membrane permeability[159], and 
the  poly  (cyanoacrylate)  backbone,  which  binds  cations  and  may  penetrate 
membranes[30].
  
1.4.5.2. Binding of proteins
After  in  vivo application  several  proteins  bind  to  polymeric  nanoparticles  by 
adsorption.  Mainly  albumin,  fibrinogen,  immunoglobulin G and apolipoproteins are 
bound to the particle surface; an overview is given in table 2. The binding of protein 
depends on their surface charge[160][161], hydrophobicity, size and shape[162]. Albumin 
and  fibrinogen  may  bind  earlier  due  to  their  high  abundance  in  blood,  whereas 
immunoglobulins  and  apolipoproteins  may  replace  them  due  to  their  higher 
affinity[163].  All  these  proteins  are  important  for  distribution  and  clearance  of 
nanoparticles in vivo[164][160].
1.4.5.3. Initiation of the adaptive immune response
Antigens are molecules that induce immune response and their contact with cells of  
the immune system initiates a defense reaction. This immune response leads to the 
production of specific antibodies directed against the antigen and the generation of  
regulatory T helper cells or cytotoxic  T lymphocytes. Antigens are processed and 
presented in association with major histocompatibility complex (MHC) class I or II  
glycoproteins  on  the  cell  surface  of  antigen-presenting  cells.  This  peptide:MHC-
complex can be recognized by T lymphocytes and activates T cells. Polysaccharides, 
glycolipids, nucleic acids and synthetic antigens may activate B cells[165].
For  its  immunogenicity  a  substance  requires  a  certain  degree  of  heterogeneity. 
Polymers formed from a single repetitive monomer are unlikely to induce an immune 
response. This applies also for the use of poly(ethylene glycol) for the masking of  
nanoparticles, which opens a wide field for more heterogeneous particles [166][49][160].
On the other hand, this gives polymeric nanoparticles properties of a hapten carrier.  
Binding a molecule to the nanoparticle surface may induce immunogenicity against 
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this molecule[167] which can be helpful if the nanoparticle is used as an adjuvant in 
vaccination, but could also induce unwanted immunologic reactions.
Table 2: Protein binding of various nanoparticles
nanoparticles / material adsorbed proteins see
polystyrene with Poloxamer 184, 188, 407 albumin, fibrinogen, IgG, apolipoproteins, 
factor B, transferrin
[168]
polystyrene with rhodamine B albumin, IgG, fibrinogen, apolipoproteins [58]
poly(cyanoacrylate) nanoparticles albumin, IgG, IgM, fibrinogen, apolipoproteins [169]
poly(butyl cyanoacrylate) with tween 80 albumin, IgG, fibrinogen, IgM, apolipoproteins [170]
poly(butyl cyanoacrylate) with dextran albumin, IgG, fibrinogen, apolipoproteins, 
serotransferrins, transthyretins 
[171]
poly(hexadecyl cyanoacrylate)  albumin, apolipoproteins, IgG, transferrin [172]
[173]
various polymers/copolymers  albumin, IgG, fibrinogen, apolipoproteins [174]
various polymers/copolymers  albumin, IgG, fibrinogen, IgM, apolipoproteins [175]
poly(ε-caprolactone)  IgG, apolipoproteins [176]
poly(lactic acid) nanoparticles with PEG albumin, fibrinogen, apolipoproteins, IgG [177]
poly(D,L-lactic acid) nanoparticles albumin, IgG, fibrinogen, IgM, apolipoproteins, 
antithrombin III 
[178]
liposomes albumin, fibrinogen, apolipoproteins, IgG, 
α-antitrypsin, α2-macroglobulin, IgM 
[179]
solid lipid nanoparticles with tween 80 fibrinogen, IgG, IgM, transthyretin, 
apolipoproteins (including apoE)
[180]
solid lipid nanoparticles with Poloxamer 188 albumin, fibrinogen, IgG, IgM, transthyretin, 
apolipoproteins (excluding apoE)
[180]
solid lipid nanoparticles with Poloxamer or 
poloxamins 
albumin, fibrinogen, apolipoproteins [181]
single-walled carbon nanotubes albumin [182]
single- and double-walled carbon nanotubes albumin, fibrinogen, apolipoproteins, 
complement factor C1q 
[183]
iron oxide nanoparticles albumin, IgG, IgM, fibrinogen, complement 
factor C3b 
[184]
1.4.5.4. Initiation of the innate immune system - Opsonization and phagocytosis
Opsonization is a process when xeno-materials are covered by molecules such as 
immunoglobulins and factors of the complement system (see table  2).  Opsonized 
surfaces  are  recognized  by  phagocytic  cells.  There  are  two  different  ways  how 
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phagocytic  cells  recognize  and attach to  their  target:  recognition  of  opsonins  via 
specific  receptors  or  non-specific  adherence  to  surfaced  absorbed  plasma 
proteins[164].  By phagocytosis,  which means uptake of the foreign materials by the 
cell, nanoparticles are removed from the bloodstream. 
The phagocytosis  of  polymeric  nanoparticles by resident  or  elicited macrophages 
induce oxidative burst and the release of toxic factors, which affect the viability of the 
macrophages[185].  If  the  polymeric  nanoparticles  are  not  biodegradable,  they 
accumulate, mainly in Kupffer cells of the liver or macrophages in the spleen [186][187]
[188]. Accumulation of foreign materials in the body will lead to side effects like chronic 
inflammation or especially in liver to cirrhosis. This process may be amplified by the 
use of apolipoprotein E as a tool to target the blood-brain barrier. The liver as main 
organ  of  the  lipoprotein  catabolism  will  take  up  a  significant  fraction  of  such 
nanoparticles[189].
1.4.5.5. Nanoparticles and blood coagulation
Blood  coagulation  is  mediated  by  platelets  and  plasmatic  coagulation  system. 
Platelets are irregularly-shaped anuclear cells of 2-3 µm in diameter. In vivo platelets 
are  activated  by  collagen,  thrombin,  ADP  or  negatively  charged  surfaces [190]. 
Activation  is  accompanied  by  a  shape  change  and  a  release  of  α-granules 
(containing platelet  factor 4,  fibronectin,  B-thromboglobulin,  von Willebrand factor, 
fibrinogen,  P-selectin  and  coagulation  factors  V  and  XIII)  and  dense granules 
(containing ADP or ATP, calcium, and serotonin). Furthermore, phosphatidylserine 
and phosphatidylethanolamine are provided on the platelet surface [191]. The released 
substances  and  surface  components  are  reactants  or  catalysts  in  blood 
coagulation[192].  Moreover,  platelets are able to aggregate, using fibrinogen or von 
Willebrand factor as connecting agents[191]. 
The plasmatic coagulation system consists of an extrinsic and an intrinsic pathway,  
which are organized in cascades. The extrinsic pathway is activated by tissue factor 
released from damaged tissue or activated cells[190]. The intrinsic pathway is activated 
via negatively charged surfaces by autoactivation of coagulation factor XII, the kinin-
kallikrein system or the complement system[193].
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Therefore, foreign and negatively charged surfaces, as presented by nanoparticles, 
induce or catalyze platelet activation as well as plasmatic coagulation [194][195][196][197].
In this work, a thrombin generation (TG) assay in platelet-rich plasma (PRP) is used 
to determine activation and activatability of blood coagulation. The newly developed 
assay monitors  the  time  course of  thrombin  activity  after  a  low activation  of  the 
extrinsic pathway[198][199][200]. Thrombin is the central enzyme of blood coagulation; it 
cleaves fibrinogen to fibrin (which forms the clot) and activates coagulation factors V, 
VIII, XI and XIII, the inhibitor protein C, platelets, fibrinolysis and is the one of the 
most  potent  activators  of  the  immune  system [190].  TG  provides  information  about 
hypo- and hypercoagulability and the impact of drugs on the coagulation system [201]
[202]. 
Furthermore, the activation of platelets by the nanoparticles is investigated by the 
determination of P-selectin (also CD62P) expression after incubation with the particle 
suspension. P-selectin is a cell adhesion molecule but only a small amount could be 
found on the surface of unstimulated platelets. After activation, P-selectin is released 
from α-granules and could be detected by specific, fluorescence-labeled antibodies 
using flow cytometry. Therefore, P-selectin can be considered as a direct marker of 
platelet activation. To discriminate platelets from other cells, Integrin α-IIb, a part of 
the constantly expressed platelet glycoprotein IIb/IIIa complex (CD41) is used as a 
second platelet-specific marker. 
On  the  other  hand,  an  alteration  of  the  coagulation  system  by  nano-  or 
micromaterials  may  be  used  as  therapeutic  or  diagnostic  option  in  coagulation-
related  diseases[83].  Nanoparticles  may  be  used  for  detection  and  treatment  of 
arteriosclerosis[203][204] or  to  target  activated  platelets[205].  Furthermore,  synthetic 
microparticles with a platelet-like surface can be used as a platelet replacement in 
patients with thrombocytopenia[206][207]. 
1.5. Physical properties of nanoparticles
To investigate properties and degradation of nanoparticles, their physical properties 
have to be considered. The interactions of photons or neutrons with the compounds 
of the particle or the particle itself provide data on composition, shape and size.
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1.5.1. Determination of basic nanoparticle properties
1.5.1.1. Size and number
With a given particle radius R ,  the particle volume V P=
4
3
R3  and particle mass 
density   the molecular weight M P  is
MP=V P P N A=
4 
3 R
3 PN A . (1)








The surface AP  of one particle is given by AP=4 R
2 , whereas the total surface AT  
of the weighted sample is
AT=N AP=3
m
 R  (3)
1.5.1.2. Surface charge
With a given surface charge Q S  with the unit [Q S ]=C m
−2  the number of charges per 





with Qe  as the elementary charge.
1.5.2. Absorbance of light
Absorbance,  also  called  optical  density,  quantifies  processes that  result  from the 
interaction of an incident light beam and the matter the light is running through. One 
of these processes is absorption, where the energy of a photon is taken up by matter,  
typically by an electron, and converted to other forms of energy, for example, to heat.  
The ability  of  a  molecule to  absorb light  of  a  certain  wavelength depends on its 
electronic properties. Molecules exhibit a variety of different activation states, defined 
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by discrete energy differences and can only  absorb photons with  an energy that 
equals  those  differences.  This  behavior  results  in  molecule-specific  absorption 
bands. On the other hand, these bands are broadened by the uncertainty principle, 
thermal  DOPPLER broadening  and  inhomogeneities  of  the  sample.  Delocalized  π-
electron systems exhibit a wide variety of possible activation states and, therefore, 
show increased absorption. The quantity of absorption depends on the concentration 
of the absorbing material, expressed in the LAMBERT-BEER law.
Furthermore, inelastic or elastic scattering may occur. The former leads to prolonged 
wavelength of the scattered photon because a part of the photon energy is absorbed 
by the molecule. Elastic scattering with unchanged photon wavelength is an ideal 
case, when no energy is transferred.
Whereas  the  absorption,  as  described  above,  depends on  the  kind  of  molecule, 
scattering,  in  particular  elastic  scattering  depends  primarily  on  the  size  of  the 
scatterer.  Thus,  the  investigation  of  the  wavelength-dependent  absorbance  of 
nanoparticles provides information about their composition and size.
1.5.2.1. Light absorption by spherical nanoparticles and size determination








2 V 1cos22   (5)
with   as the number of scattering particles per volume, V  the sample volume and 
M  the polarizability volume of the scatterer given with unit [M ]=m
3 . The scattering 
angle 2  determines the angle between the incident beam and the scattered beam, 
the  differential  cross section 
d 
d   measures the number of  photons per unit  time 
which where scattered into the solid angle   divided by incoming flux of photons. 
The total scattering cross section results from








2 V  (6)
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In diluted solutions the scattering cross section shows the same behavior like the 
absorption cross section regarding the reduction of transmittance. Resulting from the 
LAMBERT-BEER law the initial intensity of light I 0  is reduced after path length l  to the 
remaining intensity I  l   with I  l = I 0 e
− l
V . It follows that 
ln I 0I  l = lV  (7)
Introducing  the  turbidity   with =

V  and  equation  (7)  in  the  definition  of 
absorbance A=log  I 0/ I  l    results in 
A= log e l= l log e  (8)





2   (9)
wherein  the  volume  dependent  polarizability  volume  can  be  replaced  by  the 
dimensionless mean electronic polarizability   with M=
4
3





R6 2 l log e  (10)
The number  of  scattering  particles  per  volume   results  from the  initial  particle 
concentration c0 ,  the  mass  density   and  the  particle  volume V P=
4
3









 with R0  as the initial nanoparticle radius. The absorbance 
of a solution of nanoparticles finally equals
A= 32
9













From  this  equation  it  is  apparent  that  measured  absorbance  of  a  nanoparticle 
solution  depends  from the  forth  power  of  the  wavelength  .  Assuming  constant 
polarizability  it  is  possible  to  calculate  particle  radii  from absorption  data [61],  with 
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3 .  Furthermore,  it  allows  to  observe 
nanoparticle degradation by the ratio R6/R0
3
It  is  noteworthy to consider that these relations are valid for nanoparticles with  a 
diameter  smaller  than the  incident  light  wavelength.  For  objects  with  a  size  that 
equals or exceeds the wavelength, scattered waves interfere with each other, which 
leads  to  angle  dependent  amplification  or  attenuation.  In  this  case  LORENZ-MIE 
scattering theory[209] applies, which includes RAYLEIGH scattering as a special case for 
very small objects. 
1.5.3. Fluorescence emission
After  absorption  of  a  photon  a  molecule  achieves  a  higher  energy  state.  If  the 
molecule relaxes to its ground state the excess energy ends up in molecular rotation, 
vibrations, heat or the emission of an other photon with lower energy and, therefore, 
longer wavelength.
There are two different ways to achieve fluorescence emission from nanoparticles. 
Organic dyes, like fluorescein, rhodamine B or thioflavins exhibiting fluorescence due 
to  delocalized electrons in  a  conjugated system (fig. 12).  The excitation/emission 
spectra are determined by electronic effects of substituents, fluorescein emits green 
whereas rhodamine B red light. Furthermore, the spectra depend on the surrounding 
environment,  seen,  for  example,  in  the  red  shift  of  thioflavin  T  after  binding  to 
β-amyloid[143].
The  second  way  is  the  use  of  quantum  dots,  made  from  semiconductors  like 
gallium/arsenic or cadmium/selenium. These compounds allow a significant higher 
quantum yield and stability compared to organic dyes [210], the emission spectrum is 
dependent  on its  size. On the other hand,  quantum dots show a variety of  toxic 
effects  by  the  used  heavy  metals  and  possible  oxidatives.  Accumulation  in  the 
liver[211][212], cytotoxicity[211][213] and DNA damage were described[214].
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If a nanoparticle contains more than one fluorescence dye and the emission spectra 
of one dye (donor chromophore) overlaps with the excitation spectra of the other dye 
(acceptor chromophore), it is possible to study the integrity of an nanoparticle using 
FÖRSTER resonance  energy  transfer  (FRET)[215].  After  excitation  of  the  donor 
chromophore  a  part  of  the  absorbed  energy is  transferred  non-radiatively  to  the 
acceptor chromophore which emits light in addition to the emission spectra of the 
former one. The intensity of the emitted light depends on the distance between the 
dye molecules with  an inverse 6th power law based on the dipole-dipole coupling 
mechanism[215].  Due  to  the  rapidly  decreasing  intensity  the  energy  transfer  is 
constricted to a distance of lower than 10 nm. If a nanoparticle with a degradable 
shell filled with one dye and undegradable core of the other dye, FRET will occur only  
if the shell is intact. After degradation the distance between the dyes exceeds 10 nm, 
the FRET signal diminishes. This effect can be used to proof particle degradation 
within brain tissue of animals treated with nanoparticles.
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Figure 12: The fluorescence dyes fluorescein and rhodamine B
1.5.4. Light and neutron scattering
1.5.4.1. General scattering theory
Within this section an aqueous solution of light scattering particles will be discussed. 
The  solution  may  enclose  an  average  of N mol  particles  in  a  defined  scattering 
volume.  The  particles  are  numbered  with  a  running  index i  i=1, , N mol   the 
position  vector  is  defined as Ri  (fig. 13).  The vector  from the  reference point  of 
particle i  to an atom Ai  within the particle is r Ai . Thus, the position vector of the 
atom Ai  is r= Rir Ai .
The incident  beam is  scattered at  the atoms of  the  particles in  the solution,  the 
intensity of the scattered beam is detected at an angle  . The wave vector of the 
incident light is defined as ke , the wave vector of the scattered light k s  (fig. 14). 
The scattering vector q  is defined as the difference of the former two vectors.
q≡k e−k s  (12)
27
Figure 14: Scattering geometry
Figure 13: Definition of the position vectors
The differential scattering cross section 
d 
d   is the basic measurement of scattering 
processes. It is defined as scattered power d P s  into the solid angle element d   









The differential cross section can also be understood as ensemble average of the 
squared absolute value of the scattered amplitude F r   of the sample.
d 
d 
q =〈∣F q∣2〉  (14)
The sample scattering amplitude F r   is an in-phase interference of the scattering 




f i q e
−iq Ri  (15)
The  same  applies  for  the  in-phase  interference  of  scattering  amplitudes  of  the 
atoms A  of the particle i  in location r Ai . Within a particle a continuous notation is 
used to describe scattering centers with continuous scattering length densities  r  .
f i q ≡∫
V i
 r e−iqrd V  (16)
The integration  is  carried  out  over  the  particle  volume V i .  The scattering  length 
density  r   is  a measure for  the scattering strength of  the atoms in r .  In  light 
scattering this is determined by the polarizability  , whereas in neutron scattering 
the scattering strength of the atomic nucleus b  comes into play.
Typically,  the intensities of  a scattering experiment are corrected by the isotropic 
scattering of the surrounding solvent S . Therefore, the real scattering length density 
of  the  particle P r   is  reduced  by  the  scattering  length  density  of  the  solvent 
resulting in a relative scattering length density P−S r =P r −S .
f i q ≡∫
V i
P−S r  e
−iqr dV  (17)














f i q  f j* qe
−iq Ri−R j〉 . (18)
Under the assumption, that all particles in the sample are distributed uniformly, but  
irregular, and independent from each other, averaging over ∣ f i q∣











e−i q⃗ (R⃗i− R⃗ j )〉
structure function
 (19)





e−iq Ri−R j〉=N mol 1cO c2   (20)
If one uses a higher sample dilution concentration-dependent terms diminish.
d 
d 
q ≈N mol 〈∣ f i q ∣
2〉  (21)
Furthermore, it will be assumed that the particles show spherical symmetry, which is 
a usable assumption for the used nanoparticles.
P−S r ≡P r −S=
!
P r −S=P−S r   (22)
Using the GUINIER approximation the form factor 〈∣ f i q∣
2〉  for small q -values is 
〈∣ f i q ∣
2
〉=〈∣∫V i P−S r e−iqrd V∣
2〉=〈∫V i dV ′ P−S r ′e
−iqr ′∫
V i
dV ″P−S r ″e−iqr ″〉






d V ′dV ″P−S r ′P−S r ″〈e−iqr ′−r″〉
 (23)
With 〈e−iqr ′−r″〉≈1−i q r ′−r ″ 〈cos 〉−













































d V ′d V ″P−S r ′P−S r ″
 (26)
it follows, that the differential cross section of the sample 
d 
d   under the assumption 





0 ⋅1−q2 RG23  ∀ q RG≪1  (27)







q   (28)
The value V  represents the scattering volume of the sample. This results in
I q=I 0 ⋅1−q2RG23  ∀ q RG≪1 . (29)
1.5.5. Scattering of light
The propagation of light can be understood as a continuous scattering of the incident 
electromagnetic wave from every point of the illuminated medium. In uniform medium 
all rescattered secondary waves have the same amplitude, which is proportional to 
the  polarizability  at  its  originating  point,  and  interfere  destructively  except  in  the 
direction of the incident beam. If the refraction index at some point differs from its 
average value, then the resulting secondary waves do not interfere only destructively 
and light can be observed in different directions. The polarizability and the refractive 
index are connected by the CLAUSIUS-MOSOTTI-Relation. The scattered light results from 
heterogeneities within the sample; its properties are determined by the properties of 
the heterogeneity, which may be molecules or nanoparticles.
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Turbidometry and nephelometry are simple light scattering techniques, to determine 
concentrations but also aggregation, agglutination or phase separation. The former 
measures the attenuation of transmitted light (absorbance, see chapter 1.5.2.  ); the 
latter measures the intensity of scattered light at a fixed angle to the incident light.
1.5.5.1. Basic principles of light scattering
During a light scattering experiment the light scattered by the sample is detected 
under the angle  . To achieve high intensity, stability and a narrow spectrum and 
beam widening, polarized laser light is used. The scattered light is detected using 
photomultipliers or photo diodes. The scattering process is shown in fig. 15, the point 
of origin lies in the center of the scattering volume. The vectors ke  and k s  represent 
the direction of propagation of the incident and the scattered light.
ke / s=ke / s⋅
k e / s=
2 nS
e / s
k e/ s  (30)
e  and s  are the wavelengths of the incident and the scattered waves. For elastic 
scattering e= s  applies, for inelastic scattering e≠ s .  n i  and  ns  represent the 
direction of polarization, nS  the refractive index of the solvent at wavelength e / s .
For elastic scattering ∣k e∣=∣k s∣  the absolute value of the scattering vector ∣q∣  is
sin2 = ∣q∣2∣k e∣  q≡∣q∣=
4 nS
 ⋅sin2   (31)
The detection unit records count rates, a measure for scattering intensity, with a time 
resolution from 200 ns. Thereby, the time interval is shorter than dynamic processes 
within  the  sample.  Depending  on  the  evaluated  time  interval  one  differentiates 
between static and dynamic light scattering.
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Figure 15: Light scattering process
1.5.5.2. Static light scattering
If the detected signals are averaged over a long time period (e.g. 30 min), which is 
large compared with  times characteristic  for  molecular  movement  processes,  the 
information for dynamic measures like diffusion coefficients or rotational constants 
disappear. On the other hand, it is a useful method to determine molecular weight  
and radius of gyration of the scatterer. The derivation of the following equations is  
given in the appendix (see 7.3).
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O q4 RG4  . (34)




P  1M 2A2 c  (35)
and is used to interpret data from static light scattering experiment in a GUINIER plot. 
1.5.5.3. GUINIER plot
Data  from static  light  scattering  experiments  are  acquired  for  different  scattering 
angles  and sample  concentrations.  For  small  q2 RG
2  the  scattering  function  P    




















 1M 2 A2c . (37)
In a GUINIER plot lnKcR   is plotted against q2c , whereas   is an arbitrary value.
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lnKcR ≈13 q2 RG2 ln 1M 2 A2 c  (38)
A linear  fit f q2=! AB⋅q2  provides the  slope B=RG
2 /3 .  Therefore,  the  radius  of 
gyration can be calculated from RG=3B . If the refractive index increment d nD/d c   
is  known,  the  molecular  mass M  and  the  second  virial  coefficient A2  can  be 
calculated from double extrapolation of =0  and c=0 . 
1.5.5.4. Dynamic light scattering
While using dynamic light scattering, the time resolution of the scattered signal is 
recorded and averaged over time intervals   from 200 ns up to 100 s or higher. For 
time intervals lower than 10 ms movement of particles within the sample must be 
considered. Therefore, the above mentioned data interpretation has to be expanded. 
The incident light may be understood as the electrical field according to equation 34. 
This  field  polarizes  molecules  within  the  scattering  volume;  thereby,  the  charged 
compounds of the molecule (electrons, atomic nuclei) receive a force and, therefore, 
will  be accelerated. According to the classical electromagnetic theory,  accelerated 
charges  emit  electromagnetic  radiation.  The  incoming  field,  measured  at  the 
detector,  is  a  superimposition  of  all  these  emitted  fields.  Triggered  by  thermal 
interactions  the  molecules  perform  translation  and  rotary  motion  as  well  as 
intramolecular vibrations. In consequence, the detected field fluctuates in intensity 
and phase, but these fluctuations contain information about positions, orientations 
and  motions  within  the  sample.  The  function  of  dynamic  light  scattering  is  the 
connecting  of  the  gained  information  and  particle  properties.  The  theoretical 
background of dynamic light scattering is given in the appendix section (see 7.4).
In dynamic light scattering a characteristic relaxation time R  is calculated.  R  is 
related to  the translational  diffusion coefficient D .  Moreover, D  is  related to  the 




k BT  ns
2
 2
sin212 R . (39)
33
1.5.6. Scattering of neutrons
Whereas light scattering reveals information about the surface of a particle, neutrons 
are able to penetrate soft matter. The transferred energy is low and, therefore, small 
angle  neutron  scattering  (SANS)  is  a  non-destructive  methodology.  Furthermore, 
neutrons are able to penetrate aqueous solutions and are sensitive to light elements 
like hydrogen, which is important when studying biological material or polymers. On 
the other hand, SANS does not provide direct structure information like transmission-
electron or atomic force microscopy. Moreover, due to the low energy and the lack of 
charges, neutron detection efficiency is low and, therefore, time consuming.
1.5.6.1. Theoretical background of small angle neutron scattering
After transmission of the highly collimated beam through the sample, the neutrons 
are detected in an angle   typically below 5°. The scattering vector   is defined as 
given in equation 12. The differential  cross section consists of a coherent and an 
incoherent scattering fraction. 
d
d 
= d d coh dd  inc  (40)
Incoherent scattering origins from scattering of unpolarized neutrons on unpolarized 
nuclei, and results in a diffuse, angle-independent background signal. Otherwise, the 
coherent fraction results in an angle-dependent scattering pattern. 
 dd cohq=〈∣F q ∣2〉  (41)
F q  denotes the form factor of the investigated structure and equals
F q=2∫
0
∞ r r  sinqr 
q
dr . (42)
For a particle with a spherical symmetry and the radius R  the form factor equals
F q=3 sin qR−qR cosqR
qR3
 (43)
If the particle consists of several layers with the scattering length density i r   then 
equation 42 can be written as
F q=2∫0












1.5.6.2. Data acquisition and correction
To obtain radius dependent neutron intensities two different detector technologies 
are used, either ring-shaped counter tubes or a two-dimensional grid of small square-
shaped detector cells. The scattering vector q  can be calculated from the distance 
from the beam center to the detector position r . 
q=4 sin 12 arctan rLSD  . (45)
Various parameters influence variance of q , an approximation is given by









The wavelength  distribution [ 2 ]=2 /  is  determined by time-of-flight 
measurements. The resolution of the position-sensitive neutron detector depends on 
the size of a detector cell [ 2 ]PSD=2 tan 2−arctan  r−0.01/LSD /2/cos2 2  
and the collimation resolution by the length of the collimator and the diameter of the 
two pinholes [ 2 ]coll=d H12 d H22 /LCS . 
It should be noted, that the position of the beam center depends from the neutron 
wavelength. Neutrons which are used in SANS measurements are moderated within 
the neutron source to a wavelengths typically between 0.5 and 25 Å. These “cold” 
neutrons  travel  with  vn=h⋅mn
−1⋅−1  (DE BROGLIE relation)  between  7900m⋅s−1  and 
160m⋅s−1 , respectively, especially neutrons with a higher wavelength are influenced 
by gravitation. Therefore, detector grids are preferable. On the other hand, the direct 
beam must be blocked during SANS measurements, because its high intensity may 
damage the neutron sensitive detectors. The beam center has to be determined in an 
additional  experiment  using  the  direct  but  attenuated  beam.  These  additional 
measurements are also used to determine the transmittance T  of neutrons through 
the  sample.  Absorption  processes  within  the  sample,  the  solvent  or  the  cuvette 
attenuate the beam intensity  as well  as the intensity of  the scattered neutrons I  
with I ∝T . 
The intensity  of  the scattered neutrons is  determined by further  parameters.  The 
thickness d  of the used sample has two different effects. The increased number of 
scatterers  within  the  beam  increases  the  measured  intensities  with I ∝d  and 
35
decreases the transmittance which is included in T . The cross section of the beam is 
defined by a circular hole with an area A  around the sample with I ∝A . Moreover, 
the intensity is determined by the distance LSD  between the sample and the detector 
with I ∝LSD
−2 . 
In an additional measurement the neutron beam is completely blocked by a cadmium 
plate to obtain a background signal ICd  which is subtracted directly from the original 
neutron intensity measurements.  Using all  above mentioned corrections the initial  




A⋅d⋅T  I−I Cd 
. (47)
The corrected neutron scattering intensity I corr  contains the scattering signal of the 
sample as well as the scattered neutron originating from the solvent and the cuvette. 
Therefore, the signal of a cuvette only filled with the solvent is subtracted from the 
sample signal. 
Light water can be used as a calibrator for SANS measurements, the sample signal 
is corrected by the data obtained with  water,  an isotropic scatterer with  a known 
scattering  intensity   ∂∂ W .  Finally,  the  differential  cross  section  ∂∂ S  of  the 
sample  is  corrected  by  from the  measured  intensities I  (indices  S  sample,  W  
water, C  empty cuvette, b  buffer (or solvent) and background Cd )
 ∂∂ S= ∂∂ W
 I S− ICd 
LSDS
2
AS d ST S
− I b− ICd 
LSDb
2
AS d S T b




− IC−I Cd 
LSDC
2
AW dW T C
. (48)
The theoretical neutron scattering cross section of water can be estimated by the 
JACROT-factor F Jacrot  using transmission data








The factor  g  takes into  account  that,  due to  inelastic  scattering,  the intensity  is 





The error for the calculated neutron scattering intensity ( I x
*= I x−ICd ) is given by 
 ∂∂ S
 ∂∂ S
= LSDS2 T b I S* 2LSDb2 T S  I b*2LSDS2 T b I S*−LSDb2 T S I b*2 LSDC2 T W IC* 2LSDW2 T C IW* 2LSDC2 T W IC* −LSDW2 T C IW* 2 . (51)
1.5.6.3. Calculation of the coherent neutron scattering length density
The extent of neutron scattering is an atom-specific property, the neutron scattering 
length density n . The coherent neutron scattering length density n  of a particle is 
calculated from the mass density density m , the molecular weight M  and the sum 
of coherent scattering lengths b  of the each atom of the compound
n=N A
m
M ∑ b i  (52)
The neutron scattering length densities of the used substances are given in Table 3.
Table 3: Coherent scattering length density of used compounds
material sum formula m  / kg m-3 M  / g mol-1 ∑ b i  / m n  / m-2
water H2O 1000 18 -1.680∙10-15 -0.56∙1014
heavy water D2O 1106 20 19.15∙10-15 6.37∙1014
PS [C8H8]n 1050 104 23.25∙10-15 1.41∙1014
D8-PS [C8D8]n 1130 112 106.6∙10-15 6.47∙1014
PBCA [C8H11O2N]n 1120 153 32.99∙10-15 1.45∙1014
EPMA / MAA (8+1) [C7H8O2]8n+[C4H6O2]n ~1050 1061 243.1∙10-15 1.45∙1014
Thioflavin T C17H19N2S ~1200 319 51.65∙10-15 1.6∙1014
Fluorescein C20H12O5 ~1190 332 83.96∙10-15 2.5∙1014
Rhodamine B C28H31N2O3 1190 444 76.22∙10-15 1.7∙1014
Tween 80 C64H124O26 1080 1309 112.6∙10-15 0.56∙1014
PLE† C2732H4225N703O785S18 ~1400 60026 13550∙10-15 ~1.9∙1014
PLE glycoprotein / sugars‡ 1.3 -2.0∙1014
†Porcine liver carboxylesterase, amino acids 19-566[218]
‡A range is given for the eight different sugars which are contained in eucariotic glycoproteins (β -D-Glucose, β-D-Galactose and 
β-D-mannose  (all  C6H12O6),  α-L-fucose  (C6H12O5),  N-acetylgalactosamine  and  N-acetylglucosamine  (both  C8H15NO6), 
N-acetylneuraminic acid (C11H19NO9) and xylose (C5H10O5) as well as their condensation products). The total mass of the porcine 
liver esterase glycoprotein is  ~162.000 g mol-1.  PS - polystyrene, EPMA - 2,3-epoxypropylmethacrylate,  PBCA – poly(butyl 
cyanoacrylate), MAA - methacrylic acid, PLE - porcine liver esterase.
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1.5.6.4. Contrast and contrast variation
Because the neutron scattering of  a sample is not measured directly,  but  by the 
difference between the sample and the solvent signal (see 1.5.6.2), the difference in 
the neutron scattering length density of the sample and the solvent determines the 
intensity  of  the  corrected  signal.  When  using  different  solvents  it  is  possible  to 
calculate the neutron scattering length density of the sample, which can be used as a 
marker of the sample composition (Fig.  16)[219].  If  one uses an adjusted solvent a 
component of the sample is “invisible” in the measurement. This is helpful to study a 
second component in a two-component system exclusively. Therefore, in a core-shell  
nanoparticle  the  degradation  of  the  shell  can  be  monitored  when  the  solvent 
scattering length density matches the core scattering length density.
From the number N  of homogeneous spherical particles in the sample (eqn. 2), the 






sinq R−q R cos q R2 . (53)





  denotes the neutron scattering length density difference between the sample and 
the  solvent.  It  is  noteworthy,  that I 0,  is  a  non-negative  value,  although  the 
scattering length density difference may be negative and results in a v-shaped graph. 
For  the  easier  interpretation  of  the  data,  values  that  lie  above sample=solvent  are 
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Figure 16: The principle of contrast variation and matching: the observable 
intensity increases with the contrast difference; objects are "invisible" when 
embedded in a environment of the same contrast, (bright circles, contrast 
0.2; dark circles, contrast 0.6; the contrast of the environment is given below)
multiplied by −1 . If the resulting relationship between I 0,  and 2  is linear then 
the investigated sample can be considered as homogeneous. 
1.5.6.5. GUINIER plot and radius of gyration
Analogous to static light scattering there is a nearly linear relationship between the 
natural logarithm of the intensity ln  I q  and the squared scattering vector q2  for 
small values of q




A linear fit with f q2=AB⋅q2  allows direct determination of the radius of gyration 
for the used sample RG=−3B . The radius of gyration is a measure of the size of an 
object and it is calculated as the root mean square distance of the objects' parts from 
either its center of gravity or an axis. Under the assumption of small q -values and 










d r r r 2
. (56)
For a homogeneous sphere with a radius R , the neutron scattering length density   





For  a  core-shell  nanoparticle  without  polydispersity  (core RC  and C ,  shell RS  










1.5.6.6. Fit models and procedure
Because  the  above  mentioned  relationships  are  mostly  valid  for  homogeneous 
particles with no or very low polydispersity two different fit models were introduced, to 
estimate specific particle properties from I q  for greater q -values. Using equation 
44 the neutron scattering intensity of a multilayer spherical particle can be written as
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I q=K⋅2∑i=1n ∫Ri−1





Both models are based on an assumed scattering length density distribution. In the 
first model (1) the nanoparticle is assumed a spherical particle with a core radius RC , 
a shell radius RS  with corresponding contrast, and a total radius R I  (fig. 17). The 
latter  takes into account  that  the particle  surface may be inhomogeneous due to 
solvent entry. The scattering length density of the inhomogeneity is assumed to fall  





∞  ∫0RCX C rsin qr q dr ∫RC X













Furthermore,  the  radii  RC  and  RS  are  estimated  by  their  difference  to R I  with 
l=R I−RC  and  d=R I−RS . As a consequence of this definition  RC  as well as  RS  
show the same radius distribution as R I .
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Figure  17:  Nanoparticle  scattering  length  density  profile  according  to  model  1:  the 
parameters R I ,  d  and l  are fitted as well as the Gaussian distributed X . Due to the 
definition of  d  and  l  the radii RS  and RC  show the same distribution. Note, that the 
scattering length densities of nanoparticle core and shell represent the difference to the 
solvents scattering length density, therefore, also negative values are possible.
Model 1 was designed to achieve the lowest possible number of variables in a fit 
procedure. A disadvantage of this model is the uniform radius distribution of the all  
three radii. Nevertheless, it can be used to analyze homogeneous nanoparticles and 
to estimate the radius dimensions for further analysis.
In the second model (model 2) the nanoparticle consists of a core radius RC , a shell 
thickness RS , both Gaussian distributed (standard deviation X  and Y , respectively) 
and an inhomogeneity with a thickness R I  (fig. 18). The scattering length density of 
the inhomogeneity is assumed to fall linearly within R I .
In this model five variables are used in the fit procedure. Due to the variance in data, 
the broadened neutron wavelength distribution and detector dimensions it would be 
impossible to gain reliable results, especially for the widths of the radius distributions. 
On the other hand, this model can be used if cores of a core-shell nanoparticle were  
investigated separately and, therefore, the data of the shell could be estimated while 
the core data will be fixed. Furthermore, this model can be used if data from contrast 
variation series are fitted simultaneously.
41
Figure 18: Nanoparticle scattering length density profile according to model 2:  RC ,  RS  
and R I  are fitted as well as the Gaussian distributed X  and Y . Note, that the scattering 
length densities of nanoparticle core and shell represent the difference to the solvents 
scattering length density, therefore, also negative values are possible.
The definition of the variables in both models allows to reduce their number in the fit  
procedure  if  a  homogeneous  nanoparticle  is  investigated.  Furthermore,  the  used 
equations contain exclusively integrals that can be solved analytically and, therefore, 
improve accuracy and reduce computing time.
For data fitting a slightly modified NELDER-MEAD simplex method (or downhill simplex 
method) is used[220][221]. Besides the above mentioned parameters a scaling factor K  
was fitted (see eq. 59) as well as a asymptotic intensity I asy  which corrects the fact 
that the intensity may not fall to exact zero for high values of q .
1.5.7. Nanoparticle design
To  investigate  nanoparticle  structure  and  properties  different  types  of  polymeric 
nanoparticles were applied in this work. 
Core-shell nanoparticles were used for the investigation of the uptake into the brain. 
Uncoated particles as well as negatively charge polystyrene cores of early degraded 
particles  are  unable  to  cross  the  blood-brain  barrier [189].  Due  to  its  hydrophilic 
properties  early  released  dye  can  not 
cross  the  blood-brain  barrier  either 
(fig. 19).  Intact  nanoparticles  will  be 
degraded  after  endocytosis  or 
transcytosis by endothelial cells. In both 
cases  the  stable  core  may  remain  in 
place whereas the released model drug 
thioflavin  T  may  diffuse  to  its  target 
β-amyloid. The uptake can be proven by 
the  fluorescence  of  the  remaining 
particle core, the targeting of  β-amyloid 
by the fluorescence of the dye.
To investigate nanoparticle degradation 
characteristics,  homogeneous  particles 
of poly(butyl  cyanoacrylate)  as well  as 
core-shell nanoparticles were used.
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Figure  19: Principle to verify nanoparticle uptake, 
drug  release  and  targeting.  After  the  ApoE-
mediated penetration of the blood-brain barrier by 
endocytosis  or  transcytosis  the  nanoparticle  is 
degraded; the model drug, which is enclosed in the 
degradable shell (green), is released and binds to 
its target β-amyloid, whereas the stable core (red) 
remains at the site of degradation. Core particles 
from  premature  degradation  within  the  capillary 
lumen are unable to pass the blood-brain barrier 
due to the lack of the ApoE signal.
Furthermore, to investigate the influence of nanoparticle composition and surface, 
particles consisting of undegradable poly(methyl methacrylate) and poly(methacrylic 
acid) were introduced.
For the small-angle neutron scattering experiments core-shell nanoparticles are used 
to determine structure and degradation of the polymeric material. Polystyrene and 
poly(butyl cyanoacrylate) have similar neutron scattering length densities; therefore, 
perdeuterated d8-polystyrene were used to achieve a high contrast between particle 
core and shell. With these particles it is possible to observe the degradation of the 
shell material directly.
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2. Materials, devices and methods
2.1. Materials 
2.1.1. Chemical substances
Common chemicals in standard purity grade, unless otherwise noted, are purchased 
form Merck (Darmstadt, Germany), Sigma-Aldrich (Taufkirchen, Germany), Carl Roth 
GmbH (Karlsruhe, Germany), Fluka (Buchs, Switzerland) or other manufacturers.
2.1.1.1. Dyes, fluorogenic substrates
Thioflavin T, Thioflavin S and BTA-2 Sigma-Aldrich, Taufkirchen, Germany
Z-Gly-Gly-Arg-AMC Bachem, Heidelberg, Germany
2.1.1.2. Antibodies, lectins
Rabbit anti-β-amyloid SA 720 and SA 721 Schering AG, Berlin, Germany
Cy2-, Cy3- and Cy-5-tagged goat-anti-mouse IgG and IgM Dianova, Hamburg, Germany
Biotinylated-goat-anti-mouse IgG Dianova, Hamburg, Germany
Biotinylated Solanum tuberosum lectin  Vector, Burlingame, CA, USA
Cy3 and Cy5-streptavidin Dianova, Hamburg, Germany
PE-labeled anti-human GPIIb/IIIa (CD41) Beckman Coulter, Krefeld, Germany
FITC-labeled anti-human GMP (CD62P) Beckman Coulter, Krefeld, Germany
2.1.1.3. Enzymes, proteins, peptides
Porcine liver carboxylesterase EC 3.1.1.1 Sigma-Aldrich, Taufkirchen, Germany
(E 3019, activity >15 units/mg)
Lipidated tissue factor Bachem, Bubendorf, Switzerland
Biotinylated ApoE dipeptide (141-150)2 Kindly provided by Dr. M. Dathe (FMP, Berlin)
(Ac-LRKLR KRLLR LRKLR KRLLR-NH2)
2.1.1.4. Sera
Bovine serum albumin Serva, Heidelberg, Germany
Normal donkey serum Dianova, Hamburg, Germany
Normal goat serum Dianova, Hamburg, Germany
Normal rabbit serum Sigma-Aldrich, Taufkirchen, Germany
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2.1.1.5. Microscopy
Sudan Black B Merck, Darmstadt, Germany
Entellan (in toluene) Merck, Darmstadt, Germany
Glycerol / gelatin Sigma-Aldrich, Taufkirchen, Germany
Durcupan Fluka, Buchs, Switzerland
2.1.1.6. Other chemicals
Pathromtin SL Siemens Healtcare Diagnostics, Eschborn, Germany
Thrombin receptor activating peptide 6 (TRAP-6, SFLLRN)
möLab GmbH, Langenfeld, Germany
Adenosine diphosphate möLab GmbH, Langenfeld, Germany
2.1.2. Buffers and solutions
2.1.2.1. Hank's Buffered Salt Solution (HBSS)
0.137 M  sodium  chloride,  5.4 mM  potassium  chloride,  0.25 mM  disodium  phosphate  dihydrate, 
0.44 mM  monopotassium  phosphate,  1.3 mM  calcium  chloride,  1.0 mM  magnesium  sulfate  and 
4.2 mM Sodium bicarbonate in distilled water.
2.1.2.2. PBS buffer, pH 7.4
571 mg  monosodium  phosphate  dodecahydrate  (1.7 mM),  926 mg  disodium  phosphate  dihydrate 
(5.2 mM) and 8.5 g sodium chloride in 1 l deionized water.
2.1.2.3. TBS buffer (Tris-buffered saline)
12.1 g Tris(hydroxymethyl)aminomethane (100 mM) and 8.5 g sodium chloride adjusted to pH 7.4 with 
hydrochloric acid and filled up to 1 l with deionized water 
2.1.2.4. 0.05 M TBS buffer, pH 8.0
6.05 g Tris(hydroxymethyl)aminomethane (50 mM) and 8.5 g sodium chloride adjusted to pH 8.0 with 
hydrochloric acid and filled up to 1 l with deionized water
2.1.2.5. Storage buffer, TBS-NaN3 
0.2% sodium azide (w/v) in TBS buffer
2.1.2.6. Staining buffer, pH 8,0
6.05 g Tris(hydroxymethyl)aminomethane (50 mM), adjusted to pH 8.0 with hydrochloric acid and filled 
up to 1 l with deionized water
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2.1.2.7. TBS-BSA buffer
2% bovine serum albumin (w/v) in TBS buffer 
2.1.2.8. Goat, donkey and rabbit blocking solution
5% normal goat, donkey or rabbit serum and 0.3% Triton X-100 in TBS buffer
2.1.2.9. ABC-Complex
12.5 µg/ml streptavidin (stock solution: 1 mg/ml in PBS:glycerol 56:44, (v/v)) and 2.5 µg/ml biotinylated 
horseradish  peroxidase  (horseradish  peroxidase  modified  by  biotinylamidocaproyl-N-hydroxy-
succimide  ester;  stock  solution:  0.5  mg/ml  in  PBS:glycerol  56:44,  (v/v))  in  TBS-RSA,  one  hour 
incubated at room temperature[222] 
2.1.2.10. DAB-nickel solution
2 mg 3,3’- Diaminobenzidine tetrahydrochloride and 40 mg ammonium nickel sulfate hexahydrate in 
10 ml staining buffer (Tris buffer, pH 8.0)
2.1.3. Animal experiments
2.1.3.1. Mice
In the present work, two different strains of animals were investigated. 
The  APPswe/PS1(A246E)[151] double  transgenic  mouse  strain  was  crossbred  in 
C57BL/6J.  The  resulting  mice  express  amyloid  precursor  protein  (695  isoform, 
Swedish  double  mutation  K595N  and  M596L)  as  well  as  presenilin-1  (Finnish 
mutation A246E) causing an accelerated Aβ deposition in brain[151]. These mice show 
typical  signs  of  progressive  memory  impairment  dependent  on  the  amount  of 
insoluble (aggregated) Aβ42 within the hippocampus[153].
The  APPswe/PS1dE9[152] double  transgenic  mouse  strain  was  crossbred  in 
C57BL/6J. Newly generated mice express amyloid precursor protein (695 isoform, 
Swedish double mutation K595N and M596L) as well  as presenilin-1 (deletion of  
exon 9). These animals display a significant plaque number after six months[223].
The double transgenic mice were a courtesy gift of Dr. Heikki Tanila (Departments of 
Neuroscience  and  Neurology,  University  of  Kuopio,  Finland)  and  Drs.  Joanna 
L. Jankowsky  and  David  Borchelt  (Department  of  Pathology,  Johns  Hopkins 
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University, Baltimore, MD, USA), the colony founders of both APPswe/PS1dE9 and 
APPswe/PS1(A246E) mouse strains.
2.1.3.2.  Medication
Hypnomidate® Janssen-Cilag, Neuss, Germany
Xylocitin® Jenapharm, Jena, Germany
2.2. Devices
2.2.1. Microscopy
2.2.1.1. Light and fluorescence microscopy
Axioplan Carl Zeiss, Jena, Germany
Axioplan 2 Carl Zeiss, Jena, Germany
equipped with Sony DXC-930P, 3 CCD Color Video Camera
Axiophot Carl Zeiss, Jena, Germany
2.2.1.2. Confocal laser-scanning microscopy 
LSM 510 Meta NLO Carl Zeiss, Jena, Germany
TCS SP2 AOBS Leica Microsystems, Wetzlar, Germany
laser light source Argon-ion-laser, Acousto-Optical Beam Splitter
2.2.2. Photometry, fluorescence spectroscopy, flow cytometry
Anthos HTIII ELISA reader Anthos Labtec Instruments, Salzburg, Austria
Jasco V560 Spectrophotometer Jasco Corp, Gross-Umstadt, Germany
Jobin Yvon Spex Fluoromax-2 Instruments S.A., Edison, NJ, USA 
Fluoroskan Ascent Thermo Labsystems, Helsinki, Finland 
Epics XL flow cytometer Beckman Coulter, Fullerton, FL, USA
2.2.3. Animal experiments
Slide microtome Leica SM2000R Leica Microsystems, Wetzlar, Germany
Stereotaxic frame Stoelting, Wood Dale, IL, USA
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2.2.4. Small angle neutron scattering
The determination of small  angle neutron scattering is technically challenging; the 
quality  of  the  results  depends  strongly  on  the  neutron  quantity,  narrow  neutron 
wavelength  distribution  and  resolution  of  the  detectors.  Therefore,  all  three  used 
instruments and facilities (“YuMO” at Frank Laboratory of Neutron Physics, Dubna, 
“Yellow Submarine”  at  the  Budapest  Neutron  Centre  and  “V4”  at  Berlin  Neutron 
Scattering Center) are described briefly.
2.2.4.1. YuMO -  Small  angle  scattering  spectrometer  at  Frank Laboratory  of 
Neutron Physics, Joint Institute for Nuclear Research, Dubna, Russia
The YuMO  small-angle  instrument[224] is  installed  at  the  4th channel  of  the  IBR-2 
reactor (fig. 20). The IBR-2 is a pulsed neutron source[225] fueled with PuO2 which is 
cooled by liquid sodium. By means of two synchronized neutron reflectors pulses 
with a frequency of 5 Hz and a peak power of 1.500 MW are generated. During burst 
maximum 1016ncm−2 s−1  are emitted on the moderator surface.
The SANS diffractometer  YuMO operates  with  cold as well  as  thermal  neutrons. 
Therefore, the instrument needs an extensive shielding with cadmium-loaded heavy 
concrete  and  a  lockable  sample  changer  (fig. 21)  Due  to  its  time-of-flight  setup, 
neutrons are not selected by a velocity selector but by the time in which the neutrons 
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Figure  20: Experimental facilities on IBR-2 beams (small angle neutron scattering instrument 
YuMO on beam 4) and design of the IBR-2 reactor[225]
travel  from the  core  to  the  detector.  Higher  neutron  energy  results  in  a  shorter 
wavelength and a higher speed (DE BROGLIE relation). 
The  neutron  flux  on  the  sample  reaches  107−4⋅107ncm−2 s−1  with  a  q-range  of 
7⋅10−3−0.5Å . Using the cold moderator the neutron wavelength ranges from 0.5 to 
8 Å. The scattered neutrons are detected time-dependently by two ring detectors, 
each detector consists of eight independent 3He-filled wires
He3 n p H3  (61)
Furthermore, the sample transmission is detected by a direct beam detector based 
on 6Li. The calibration can be done by an insertion of a movable vanadium standard.
2.2.4.2. Yellow Submarine - SANS diffractometer at Budapest Neutron Centre
SANS diffractometer at the Budapest Neutron Center is placed on beam 2 in the 
CNS measuring hall originating from the Budapest Research Reactor BRR (fig. 59). 
This  reactor  is  a  tank-type  reactor,  moderated and cooled by light  water [226].  The 
neutrons are  produced using  VVR-SM rods (235U) and beryllium based  reflectors 
which result in a nominal thermal power of 10 MW and a neutron flux of in the core.
Due  to  the  continuous  neutron  flux  the  neutron  wavelength  is  determined  by  a 
mechanical multi-disk velocity selector ranging from 3 to 25 Å. The instrument covers 
a the transferred momentum (q-range) from 0.003 to 0.5 Å-1 allowing to measure 
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Figure 21: View into the experimental hall (left) and on the YuMO cuvette holder (right) at 
the Frank Laboratory of Neutron Physics, Dubna
density compositions on a length scale from 5 up to 1400 Å [227]. Samples are placed 
in  a  automatic  sample  changer  (fig. 23)  and  can  be  tempered  between  -30  and 
150°C.  The  neutron  flux  at  the  sample  is  5⋅107ncm−2s−1 ,  scattered  neutron  are 
detected by a movable 2D multi-detector with 64 x 64 square cells each 1 cm2 filled 
with BF3. The detector measures indirectly the induced release of charged α particles
B10 n Li7  (62)
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Figure  23:  Small  angle  neutron  scattering  detector  "Yellow  Submarine"  (left)  and 
automatic sample changer (right) at Budapest Neutron Centre
Figure 22: Budapest Research Reactor and experimental facilities on BNC, Budapest[226]
2.2.4.3. V4  -  Small  Angle  Neutron  Scattering  Instrument  at  Berlin  Neutron 
Scattering Center at Hahn-Meitner-Institute
The research reactor BER II is a light water cooled and moderated reactor operating 
at  10 MW  thermal  power[228].  The  core  operates  with  24  fuel  elements  and  six 
additional  control  elements  consisting  of  low  enriched  uranium.  The  core  is 
surrounded  by  beryllium  reflectors  where  the  neutron  flux  amounts  to 
1.2⋅1014n cm−2s−1 . The cold source is operated with hypercritical hydrogen at about 
25 K and 14-17 bar; cold neutrons from the moderator are delivered by eight curved 
neutron guides into the experimental hall (fig. 24).
The small  angle neutron diffractometer V4 is installed at the neutron guide NL3a. 
Incoming  neutrons  are  monochromatized  by  a  mechanical  velocity  selector  with 
variable wavelength resolution (from 8% to 18%) and collimated on a variable length 
from 1 to 16 m. A high transmission supermirror allows the use of polarized neutrons 
and can be introduced by remote control. 
Neutron flux at sample is up to  2⋅107ncm−2 s−1 . The automatic sample changer is 
placed in a pressure vessel to avoid scattering from air humidity and to allow setups 
with  different  temperatures  and  pressures  (fig. 25).  The  neutron  detector  can  be 
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Figure 24: The research reactor BER II and neutron scattering instrumentation at BENSC, 
Berlin[228]
moved from a sample detector distance of 1 m up to 16 m. It consists of a 2D 3He 
gas detector with a size of 64 x 64 cm2 with a pixel size of 5 x 5 mm. The data are 
acquired  in  a  histogram  mode  but  also  allow  a  list  mode  for  time-stamped 
experiments.
2.2.5. Light scattering, ALV/DLS-5000 compact goniometer system
The ALV/DLS-5000 compact  goniometer  system (ALV GmbH, Langen,  Germany) 
allows  simultaneous angular  dependent  determination  of  dynamic  and static  light 
scattering systems. A scheme of the basic setup is given in fig. 26. 
52
Figure 26: Layout of the ALV-5000 compact goniometer system
Figure 25: The SANS diffractometer V4 at BENSC, Berlin[228]
Laser light source is a 120 mW frequency-doubled continuous wave diode-pumped 
Nd:YAG laser (DPY 315 II, AdLas GmbH, Lübeck, Germany) with a wavelength of 
532 nm. To achieve a longtime stable signal and a prolonged durability, the laser was 
operated at about 50 mW. The diverted beam from the first beam splitter is used in a 
differential refractometer to determine the refraction index increment of the sample. 
Two adjustable mirrors are used to guide the beam into the center of the detection 
system. The beam may enter and leave the vat exactly perpendicular to the vat wall.  
Between the second mirror and the vat an liquid crystal attenuator is placed (model 
932-CX, Newport Cooperation, Irvine, CA, USA), as well as a second beam splitter  
and a focus lens). At the second beam splitter the intensity and spatial stability of the 
attenuated  laser  beam is  determined  using  a  4-quadrant  photo  diode.  A  shutter 
allows to block the beam, which is needed to protect the detection system when the 
sample is changed.
The vat  is filled with toluene which fits the refractive index of the vat as well  the 
cylindrical sample cuvettes to avoid reflections. The vat is placed in a socket which 
contains a sample holder, a temperature control system and the detection system. 
The latter consists of a rotatable base, high-precision step motor, a detection unit to 
focus on the scattering volume, and a photomultiplier. The time-dependent counting 
53
Figure  27:  ALV-5000 compact  goniometer  system (see  fig.  26 for  layout 
details, view from the right side)
rate is analyzed by a auto correlator (ALV-5000 multiple tau digital correlator), and 
the resulting data were analyzed with an attached computer.
During this work the ALV/DLS-5000 compact goniometer system was disassembled, 
rebuild  and  newly  adjusted.  The  manual[229][230] gives  only  a  short  description, 
therefore, a detailed description for the vat socket and vat adjustment is given by 
Steffen Lindert[219], whereas a description of the focus lens and the photomultiplier 
adjustment is provided in the result section (see chapter 3.2.1. ).
2.2.6. Software
Text OpenOffice.org 3.2 Writer
Tables OpenOffice.org 3.2 Writer, Microsoft Office Excel 2003
Figures ACD/ChemSketch  12,  Adobe  Illustrator  CS2,  IrfanView  4.20,
Microcal Origin 5, Microsoft Office Excel 2003, Microsoft Office 
PowerPoint 2003, Waterloo Maple 7




All used nanoparticles were synthesized by Dr. Bernd-Reiner Paulke [32], Fraunhofer 
Institute for Applied Polymer Research, Science Center Golm. The nomenclature of 
the nanoparticles was given by Dr. Paulke. The nanoparticles were named 'HL' for 
'Härtig Latices' followed by a consecutive number.
Thioflavin T is bound non-covalently to the nanoparticles by inclusion or adsorption, 
this also applies  for thioflavin S. The dye rhodamine B is bound covalently to the 
nanoparticles. 
2.3.1.1. Polystyrene core HL-22 (core of HL-23)
166 ml of ultra-pure water were mixed with 10 ml of absolute ethanol, 27 mg sodium 
tetraborate, 30 mg thioflavin T and 300 mg sodium dodecyl  sulfate.  Under stirring 
(350 min-1) and nitrogen gassing 12 g styrene were added under nitrogen gassing 
within 20 minutes. The continuously stirred mixture was heated up to 60°C (reflux 
condenser) for 24 hours. Next, the reaction was started by adding 134 mg potassium 
peroxidisulfate  in  20 ml  ultra-pure  water.  The  resulting  intensive  colored  colloidal 
polymer dispersion with a solids content of 5.6% was dialyzed for 7 days. The final 
dispersion contains a solids content of 4.8% with a mean particle radius of 34 nm.
2.3.1.2. PS-PBCA core-shell nanoparticles HL-23
20.7 ml dialyzed latex HL-22 (equals 1 g) were primarily mixed with 2 g Poloxamer 
188 and 5 mg thioflavin T. The solution was then adjusted to pH 2 with hydrochloric 
acid  and  filled  up  to  200 ml  with  ultra-pure  water.  Subsequently,  2 g  butyl 
cyanoacrylate were added under stirring (400 min-1) for 4 hours at 4°C. The reaction 
mixture  was  neutralized  with  sodium  hydroxide  and  the  resulting  core-shell 
nanoparticles  were  purified  by  dialysis  and  ultracentrifugation.  Resulting  particles 
displayed a radius of 64.5 nm and a solids content of 2.2%.
2.3.1.3. PS cores HL-28 and PS-PBCA core-shell nanoparticles HL-29
HL-28 was synthesized analogous to HL-22; HL-29 was coated on HL-28 analogous 
to HL-23. In both preparations thioflavin T was replaced by thioflavin S. 
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2.3.1.4. PS cores HL-30 and PS-PBCA core-shell nanoparticles HL-33
HL-30 was synthesized analogous to HL-22 using 5 mg of thioflavin T; HL-33 was 
coated on HL-30 with additional 5 mg thioflavin T as well.
2.3.1.5. PS cores HL-31 and PS-PBCA core-shell nanoparticles HL-32
HL-31 was synthesized analogous to HL-22 without any dye; HL-33 was coated on 
HL-28 with additional 5 mg thioflavin T.
2.3.1.6. PS core HL-49, PS-PBCA core-shell nanoparticles HL-50 and HL-50T
HL-49 and HL-50 were synthesized like HL-22 and HL-23, respectively. The surface 
of HL-50 was coated with polysorbate 80[231] and the coated nanoparticle was named 
HL-50T. 
2.3.1.7. Polymethacrylate nanoparticles HL-35 up to HL-42
176 ml of ultra-pure water were mixed with 4 ml of absolute ethanol, 140 mg sodium 
tetraborate,  200 mg carbowax 6000,  500 mg sodium dodecyl  sulfate  and 500 mg 
sodium dodecyl sulphopropyl maleate. Furthermore, different mixtures of methacrylic 
acid (MAA), methylmethacrylate (MMA), hydroxyethylmethacrylate (HEMA) and 2,3-
epoxypropylmethacrylate (EPMA) as well as thioflavin T (see table 4). The reaction 
was started routinely by adding 100 mg potassium peroxidisulfate in 20 ml ultra-pure 
water and stirred overnight at 350 min-1at 60°C.
Table 4: Monomer and dye composition of HL-35 up to HL-42 (abbreviations see above) 
name monomers thioflavin T content
HL-35 4 g EPMA, 0.5 g MAA 10 mg
HL-36 4 g EPMA, 0.5 g MAA 20 mg
HL-37 4 g EPMA, 0.5 g MAA 30 mg
HL-38 4 g EPMA, 0.5 g MAA 45 mg
HL-39 2 g EPMA, 2 g MAA 10 mg
HL-40 1 g EPMA, 3 g MAA 10 mg
HL-41 0.5 g EPMA, 0.5 g HEMA, 3 g MMA 10 mg
HL-42 3.5 g MMA, 0.5 g MAA 10 mg
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2.3.1.8. Core-shell nanoparticles RB-FIX2-PBCA-TF and RB-FIX3-PBCA-TF
The cores of both nanoparticles were synthesized with 10.8 g styrene in 196 ml ultra-
pure water. Red fluorescent rhodamine B was added, which is bound covalently to  
1 g or 0.5 g epoxypropylmethacrylate or RB-FIX2-PBCA-TF and RB-FIX3-PBCA-TF, 
respectively. After dialysis, the particles shells were made analogous to HL-23 with 
thioflavin T as dye. 
2.3.1.9. PS-PBCA core-shell nanoparticle with perdeuterated polystyrene
To achieve a different neutron scattering length density between nanoparticle core 
and shell for SANS experiments, these particles synthesized like HL-22 and HL-23, 
but the cores are made of perdeuterated styrene. The particles were named HL-51 
(core) and HL-52 (core-shell particle).
2.3.1.10. Polymethacrylate nanoparticles 2003/I-SA and 2003/I-SA/ApoE
The nanoparticle 2003/I was synthesized analogous to HL-35 and streptavidin was 
coupled  to  the  nanoparticle.  Therefore,  5 mg  1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide 10 ml to an 1.1% suspension, 10 µmol streptavidin was added under 
stirring. After 4 h the solution was dialyzed for at least five times. A biotinylated ApoE 
dipeptide (ApoE (141-150)2,  Ac-LRKLR KRLLR LRKLR KRLLR-NH2) was incubated 
overnight with the particle suspension (0.2 mg in 20 ml)[119].
2.3.2. Animal experiments
All animal experiments were performed at the University of Leipzig and approved by 
the Animal Care and Use Committee of the University of Leipzig (TVV 9/04). 
2.3.2.1.  Intrahippocampal and intracerebroventricular nanoparticle application 
Animals  were  anesthetized  with  an  intraperitoneal  injection  of  etomidate 
(Hypnomidate; 33 mg/g body weight). In addition, local anesthesia at the skull was  
achieved with  a  subcutaneous injection  of  1% lidocaine hydrochloride  (Xylocitin).  
Next,  their heads were mounted in a stereotaxic frame (Stoelting, Wood Dale, IL, 
USA).  Thereafter,  1–2 µl  of  a  nanoparticles  suspension  or  the  free  thioflavins 
(2 mg/ml)  were  injected  into  the  dorsal  hippocampus  (AP = #1.7 mm,  L = 1 mm, 
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DV = 2 mm, relative to bregma). Intracerebroventricular (i.c.v.) injections were done 
with 5 µl of selected substances. 
2.3.2.2. Intravenous nanoparticle application
Mice were anesthetized with an intraperitoneal injection of etomidate (Hypnomidate; 
33 mg/g body weight). 10 - 20 µl of nanoparticles were injected into the tail vein.
2.3.2.3. Collecting mouse organs, fixation, storage and sectioning
Three  days  post-injection,  the  mice  were  transcardially  perfused  with  4% 
paraformaldehyde  and  0.1%  glutaraldehyde  in  0.1  M  sodium  phosphate  buffer, 
pH 7.4. Brains were post-fixed in 4% paraformaldehyde overnight and subsequently 
cryoprotected in 30% sucrose in phosphate buffer. Liver, lung, heart, kidneys and 
spleen of mice received intravenous nanoparticle application were cryoprotected in 
30% sucrose in phosphate buffer. Frozen sections were cut at a thickness of 30 µm 
with a freezing microtome and collected in 0.1 M Tris-buffered saline, pH 7.4, (TBS) 
containing sodium azide.
2.3.3. Histochemistry and immunohistochemistry
2.3.3.1.  Histochemical detection of thioflavins
For the analysis of fibrillar Aβ labeled with thioflavins in vivo, sections were washed 
with TBS, dipped in distilled water, mounted onto fluorescence-free glass slides, air-
dried and coverslipped with Entellan or glycerol/gelatin.
2.3.3.2. Histochemical detection of Solanum tuberosum lectin
For the detection endothelial cells free-floating sections were blocked with 5% normal 
goat serum in TBS containing 0.3% Triton X-100 for at least 1 h. Next, the sections 
were incubated overnight  at room temperature  with 20 µg/ml biotinylated  Solanum 
tuberosum lectin in the blocking solution. After thorough rinsing in TBS, the sections 
were reacted with Cy3- or Cy5-streptavidin (10 µg/ml or 20 µg/ml in TBS containing 
2% bovine serum albumin, respectively) for 1 h, rinsed and processed as above. 
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2.3.3.3. Immunohistochemical detection of β-amyloid
For  the  concomitant  detection  of  thioflavins  and  immunostained  β-amyloid,  free-
floating sections were processed with a rabbit antiserum directed against a central  
amino acid sequence of β-amyloid (SA 720 or SA 721). First, the tissue was blocked 
with 5% normal goat serum in TBS containing 0.3% Triton X-100 for at least 1 h. 
Next, the sections were incubated with rabbit anti-β-amyloid (1:1500 in the blocking 
solution) overnight.  After  thorough rinsing in TBS, the sections were reacted with 
Cy3-conjugated goat anti-rabbit IgG (20 µg/ml in TBS containing 2% bovine serum 
albumin) for 1 h. Finally, the sections were rinsed and processed as above.
2.3.3.4. Histological controls
Histological controls were carried out by omitting the primary antibodies resulting in 
the absence of any red fluorescent immunosignal.
2.3.3.5.  Quenching of autofluorescence
To quench autofluorescence of the tissue, some sections were treated with Sudan 
Black B[232], mounted and coverslipped in glycerol/gelatin.
2.3.4. Photoconversion for electron microscopy
Fluorescence-labeled  tissue  sections  were  incubated  in  a  solution  consisting  of 
1.5% DAB  and  1.5% potassium  cyanide  in  0.1 M  PBS  pH 7.4  for  30  minutes. 
Subsequently,  the tissue was placed on a wet filter paper in a closed conversion 
chamber[233] and again incubated in the DAB solution. After the solution was sucked 
off  with  a  pipette,  the  chamber  was closed and filled  with  oxygen.  Fluorescently 
labeled structures were  illuminated with  a 20x long distance objective of  a Zeiss 
Axiophot  microscope  with  a  HBO-100W  lamp  until  the  fluorescence  has  faded. 
Thereafter, the sections were washed three times for 15 minutes in cold buffer and 
transferred  into  1%  buffered  osmium  tetroxide  solution  for  10-15  minutes.  The 
sections were dehydrated in ascending series of ethanol, including blockstaining with 
uranyl acetate. For ultrathin sectioning the tissue was embedded in Durcupan.
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2.3.5. Thrombin generation assay
Fresh drawn citrate blood was centrifuged for 10 minutes at 170 g to obtain platelet-
rich plasma. Platelet-poor plasma (PPP) was prepared by double centrifugation of 
platelet-rich plasma at 2860 g each time for  20 minutes.  The nanoparticles were 
diluted 1:20 in PPP or PRP, respectively.
The  fluorogenic  substrate  used  for  thrombin  generation  was  Z-Gly-Gly-Arg-
aminomethylcoumarin at a concentration of 0.24 mM. It has a low affinity to thrombin 
and is consumed slowly. This avoids a premature plateau of the fluorescence curve 
due  to  substrate  depletion.  The  start  reagent  with  the  fluorogenic  substrate  also 
contains dimethyl sulfoxide (diluted 1:21), isotonic saline (0.3 g/l), CaCl2 (16 mM), tris 
puffer (pH 7.4, diluted 1:10), as well as an exogenous and an endogenous activator 
(tissue factor and pathromtin SL, respectively, each at a dilution of 1:1250). 
25 µl of the reagent was added to 100 μl of PRP or PPP. Fluorescence intensity was 
detected using the Fluoroscan Ascent 2.2 at wavelengths of 340 nm (excitation wave 
length) and 440 nm (emission wavelength).  The measurement lasted 120 minutes 
and  ETP was  given  as  arbitrary  units  of  fluorescent  activity  (FU),  the  maximum 
reaction velocity as FU s-1.
2.3.6. Platelet activation by flow cytometry
Blood  was  drawn  using  a  21-gauge  needle  into  5 ml  syringes  containing  3.8% 
sodium citrate and incubated with nanoparticle suspension (dilution 1:20) at 37°C for 
30 minutes. Thereafter, blood was diluted 1:10 in HBSS with 1% BSA (total volume 
500 µl),  the  nanoparticles  were  added  to  a  final  dilution  of  1:20.  Aliquots  of  the 
platelet suspension were activated for 10 minutes with ADP (final concentration 5µM) 
or TRAP-6 (10µM); native non-activated whole blood from the same sample served 
as control. The aliquots were incubated at 37°C with saturating concentrations of a 
murine PE-labeled anti-GPIIb/IIIa (CD41) monoclonal antibody and a murine FITC-
labeled anti-GMP 140 (CD62P) monoclonal antibody. Platelet activation and staining 
were stopped after 5 minutes by adding 2 ml of 4°C HBSS buffer. 
The activation of platelets was determined by flow cytometry. Platelet fragments as 
well as aggregates were excluded by gating platelets in the forward scatter signal. 
CD41-negative  cells  were  excluded  by  a  discriminator.  Platelet  activation  was 
determined by the intensity of the CD62P expression.
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3. Results
3.1. Physical properties of nanoparticles
3.1.1. Absorbance spectra of polymeric nanoparticles
For the PBCA nanoparticles HL-50 a linear relationship between absorbance and the 
inverse  4th power  of  the  wavelength  was  found  (fig. 28).  The  signal  was 
superimposed by the absorbance from polystyrene and PBCA at about 350 nm and 
the  dye  thioflavin T  at  420 nm  but  the  spectrum  was  dominated  by  RAYLEIGH 
scattering.
On the other hand, the spectra of the EPMA/MAA nanoparticles were superimposed 
by a significant absorbance of thioflavin T, besides this a linear relationship between 
absorbance and the inverse 4th power of the wavelength was observed (fig. 29).
For the double-fluorescent particles RB-FIX2-TF-PBCA and RB-FIX3-TF-PBCA two 
absorbance peaks for the dyes were observed (fig. 29). 
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Figure  28: Absorbance spectrum of HL-50 (3 g/l); the absorbance (green dots) closely 
follows a inverse 4th power law with respect to the wavelength, which is composed of 
RAYLEIGH scattering (black line) and absorption (blue line); absorption is caused by the 
polymers  (PS and  PBCA,  ~350 nm)  and  Thioflavin  T  (~420 nm),  the  fluctuations  are 
caused by discrete steps of the signal intensity, the gaps are caused by changing mirrors  
in the analyzer (Jasco V560 UV-VIS Spectrophotometer).
For the EPMA/MAA nanoparticles an almost linear relationship between the slope of 
absorbance over the inverse 4th power of the wavelength was found (fig. 30).
3.1.2. Degradation of nanoparticles observed by absorbance measurements
Degradation  experiments  were  performed  by  incubating  HL-50  and  HL-50T  with 
porcine liver esterase (fig. 31) at 37°C in a PBS buffered solution. 
The  change  in  the  absorbance  was  measured  at  multiple  wavelengths  and  was 






Figure  29:  Absorbance spectra of polymeric nanoparticles. HL-35 (left,  3 g/l)  and 2003/I-SA (right, 
3 g/l); absorbance (green dots); RAYLEIGH scattering (black line) is superimposed by strong absorption 
of thioflavin T (left, blue line) or rhodamine B (right, blue line); Jasco V560 UV-VIS Spectrophotometer
Figure  30:  Relationship  between  nanoparticle  radius  (EPMA/MAA) 
and absorbance over the inverse 4th power of the wavelength 
At   is the absorption of the sample at time t , A∞  is the asymptotic value of A  for 
large t  (here t  > 13 h) and A0  is the initial absorption. The normalized absorption 
An t   is a measure for the degree of PBCA nanoparticle degradation.
The degradation lasted several hours. A relationship was found between reaction 
velocity  and enzyme concentration.  If  the  concentration  of  the  nanoparticles  was 
increased,  the  time  until  complete  degradation  was  prolonged.  Furthermore,  the 
polysorbate 80-coating of HL-50T slowed down the reaction velocity (tab. 5).
The  linear  relationship  between  absorbance  and  the  inverse  4 th power  of  the 
wavelength was not affected during the measurements (data not shown).
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Figure  31:  Enzymatic  degradation  of  PBCA  nanoparticles 
HL-50  with  porcine  liver  esterase  in  vitro  at  37°C. 
Spectrophotometric measurement of  the time course of the 
normalized  absorption  An(t)  at  405 nm correlating  with  the 
degree of degradation. Only every 8th data point is shown as 
average value from at least three experiments. The standard 
deviation was found to be less than 5 % and is not shown. 
(top) Degradation of HL-50 (3 g/l) with different porcine liver 
esterase concentrations. 
(center)  Degradation  of  different  concentrations  of  HL-50 
suspensions with 0.5 mg/ml esterase. 
(bottom) Comparison between the degradation of HL-50 and 
polysorbate 80 coated HL-50T with 0.5 mg/ml esterase.  
Table  5:  Degradation  of  nanoparticles  in  dependence  of  particle  and  enzyme  concentration  and 
particle surface modification
Nanoparticle Enzyme concentration Half-life
HL-50 (3 g/l) 0.25 mg/ml 3.6 h
HL-50 (3 g/l) 0.5 mg/ml 2.8 h
HL-50 (3 g/l) 2.0 mg/ml 1.8 h
HL-50 (1 g/l) 0.5 mg/ml 0.7 h
HL-50 (2 g/l) 0.5 mg/ml 2.1 h
HL-50T (3 g/l) 0.5 mg/ml 5.6 h
3.1.3. Fluorescence spectra
Excitation-emission  spectra  of  the  nanoparticles  were  obtained.  Thioflavin T- 
containing particles showed strong fluorescence (fig. 32) with a maximum at 419 nm 
(excitation) and 466 nm (emission).
The double-fluorescent particles RB-FIX2-TF-PBCA and RB-FIX3-TF-PBCA showed 
a trimodal spectrum (fig. 33) with the first peak at 419 nm and 466 nm (thioflavin T) 
and the second peak at  564 nm and 583 nm (rhodamine B). The third peak could be 
found at 419 nm (excitation) and 583 nm (emission) induced by  FÖRSTER  resonance 
energy  transfer;  energy  was  absorbed  by  thioflavin T,  the  light  was  emitted  by 
rhodamine B.
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Figure 32: Excitation-emission spectrum of HL-50 (3 g/l)
3.2. Nanoparticle analysis by light scattering 
3.2.1. Adjustment of the ALV/DLS-5000 compact goniometer system
A detailed  description  for  the  vat  socket  and  vat  adjustment  is  given  by  Steffen 
Lindert[219]. Thereafter, the focus lens is placed directly in front of the vat socket. The 
vat is filled with toluene, no sample is placed in the vat. Both horizontal and vertical  
micrometer gauge are used to adjust the focus lens. Goal of the adjustment is a high 
signal  intensity  and  a  low  slope  over  the  entire  angle  range.  Angle  dependent 
measurements  were  performed  using  different  positions  of  the  vertical  and  the 
horizontal micrometer gauge (fig. 34). 
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Figure 33: Excitation-emission spectrum of RB-FIX2-PBCA-TF (3.8 g/l)
Figure 34: Focus lens adjustment, the final position was 9.00 mm (horizontal) and 8.77 mm (vertical)
No  micrometer  gauges  are  installed  at  the  photomultiplier  unit.  Using  the  same 
instrument setup, the horizontal and vertical adjustment screws of the photomultiplier 
were  loosen.  Measurements  were  done  with  by  a  clockwise  quarter-turn  of  the 
adjustment screws below the photomultiplier and on one side. The opposite screws 
were loosen before and tighten after the adjustment (fig. 35). .
3.2.2.  Determination of nanoparticle radii by light scattering
For the determination of nanoparticle radii the original solutions must be diluted to 
give an adequate intensity but avoid multiple scattering processes by high particle 
content. Using dynamic light scattering, low standard deviation between measure-
ments  and low angle dependency were  found between particle  concentrations of 
3.75 and 12.5 mg/ml (fig. 36). 
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Figure  36:  Hydrodynamic  radius  of  nanoparticles  HL-22  depending  on  particle 
concentration (left) and scattering angle (right). The radii are calculated by a “Simple fit” 
using the ALV software from dynamic light scattering data.
Figure 35: Photomultiplier adjustment, final position was 1 turn (horizontal) and 1.25 (vertical)
The concentration-dependent data can be further used in a GUINIER plot (see eqn. 38), 
where the  RAYLEIGH ratio  ln K c /R   is  plotted against  q2⋅c  (fig. 37).  For  each 
concentration the slope is determined by f q2=! AB⋅q2 , and the radius of gyration 
can be determined by RG=3 B  (tab. 6).
The  molar  mass  and  the  second  virial  coefficient  A2  (see  equation 38)  can  be 
determined by double extrapolation to  c=0  and  =0  only if the refractive index 
increment  of  sample  is  known.  The  refractive  index  increment  could  not  be 
determined  for  the  nanoparticles  due  to  a  lack  of  reliable  data.  The  radius  of 
gyration RG  of a sphere is connected to its real radius R  by R2=5/3⋅RG
2 .
Table 6: Radius determination by static (radius of gyration RG ) and static light scattering (hydro-
dynamic radius Rhy ) for polymeric particles, all radii in nm
Concentration RG (HL-22) Rhy (HL-22) RG (HL-23) Rhy (HL-23) RG (HL-31) Rhy (HL-31)
50 mg/l 26.1 36.2 ± 0.2 30.7 41.1 ± 0.4
25 mg/l 25.9 36.0 ± 0.1 30.9 41.0 ± 0.5
12.5 mg/l 23.7 35.5 ± 0.2 31.3 40.8 ± 0.3
10 mg/l 55.9 67.5 ± 2.8
6.3 mg/l 26.2 35.2 ± 0.2 30.6 40.4 ± 0.2
3.1 mg/l 27.7 35.0 ± 0.2 31.5 40.7 ± 0.3
Average 25.9 ± 1.4 35.6 ± 0.5 55.9 67.5 ± 2.8 31.0 ± 0.4 40.8 ± 0.3
Radius R 33.8 ± 1.8 72.2 40.0 ± 0.5
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Figure 37: GUINIER plot of polystyrene core HL-22 ( =1017 )
The nanoparticle type HL-50 was compared with  HL-50T,  which was coated with 
polysorbate 80 to increase biocompatibility; hydrodynamic radii were determined with 
49.6±3.4 nm and 50.1±2.6 nm, respectively.  The coating can be estimated with  a 
thickness of 0.5 nm.
3.2.3. Monitoring of nanoparticle degradation
Degradation  of  core-shell  nanoparticles  was  monitored  using  light  scattering. 
Therefore,  2 g/l  of  the nanoparticle  suspension were  incubated with  0.5 mg/ml  of 
porcine liver esterase at 37°C. At defined time points between 30 minutes and 24 
hours a 50 µl aliquot of the suspension was diluted in 9950 µl PBS buffer at 4°C to 
stop  the  ongoing  reaction.  Samples  were  measured  using  static  light  scattering 
(fig. 38).  Unexpectedly,  the  particle  radii  increased  (HL-50)  or  stayed  nearly 
unchanged (HL-52).  Data  from dynamic  light  scattering  were  not  analyzable,  but 
indicate larger aggregates.
The aggregation may be induced by the neutralization of the negative charges of the 
polystyrene  particles.  Hence,  polystyrene  nanoparticles  HL-31  were  mixed  with 
various amounts of the positively charged thioflavin T and revealed concentration-
dependent  aggregation  between  100  and  2000 µmol  thioflavin T  per  gram 
nanoparticles.
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Figure  38:  Degradation of  polymeric  core-shell  nanoparticles  (right:  HL-50,  left:  HL-52)  monitored 
using static light scattering. The increase of radii may be explained by aggregated core particles
3.3. Nanoparticle analysis by small angle neutron scattering 
If not noted otherwise, nanoparticles were investigated at a concentration of 2 g/l. 
Data correction were performed by provided or self-written software.
3.3.1. Radius determination
Nanoparticle radii could be estimated using the GUINIER law; for low values of q  the 
radius of gyration can be calculated from the slope of ln  I q  over q2  (fig. 40).
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Figure  39:  Polystyrene  nanoparticles  HL-31  showed  concentration-
dependent  aggregation  when  mixed  with  thioflavin  T  (dynamic  light 
scattering data).
Figure 40: Radius determination by small angle neutron scattering using GUINIER law: D8-polystyrene 
core HL-51 (left) and core-shell particle HL-52 (right); slope and 99% confidence interval. Measured at 
spectrometer V4, BENSC, Berlin
A list of determined nanoparticle radii is given in table 7.
Table 7: Radius determination by small angle neutron scattering using GUINIER law
radius of gyration RG / nm
Particle X(D20)=0.0 X(D20)=0.1 X(D20)=0.3 X(D20)=0.5 X(D20)=0.8 X(D20)=0.95 Device
HL-22 27.3 27.3 27.4 26.8 27.1 YuMO
HL-31 31.4 31.6 31.3 30.4 31.1 YuMO
HL-49 29.9 YelSub
HL-50 39.2 YelSub
HL-51 21.5 21.5 YuMO
HL-51 23.6 V4
HL-52 58.6 52.4 59.5 61.1 V4
2003/I-SA 19.3 20.0 28.7 12.4 YelSub
Devices: “YuMO” - SANS spectrometer YuMO, JINR, Dubna; “YelSub” - SANS spectrometer “Yellow submarine”, BNC, 
Budapest and “V4” - SANS spectrometer V4, BENSC, Berlin
3.3.2. Contrast variation
Contrast  variation experiments were  used to  determine the particle  contrast.  The 
achieved data were compared to theoretical values; if the measured contrast equals 
the  estimated  contrast  a  homogeneous  particle  can  be  assumed.   I 0/c , 
extrapolated  from  the  GUINIER plot,  is  plotted  over  the  solvent  contrast,  usually 
X D2O ; to simplify the data analysis, values above the estimated particle contrast 
are multiplied with -1 and the interception with the X-axis is calculated (fig. 41). 
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Figure  41:  Determination  of  sample  contrast  using  contrast 
variation;  EPMA/MAA  nanoparticle  2003/I-SA,  Measured  at 
“Yellow submarine”, BNC, Budapest
Table  8 shows  sample  contrasts  determined  for  various  polymers.  For  all  used 
polymers, the measured and the theoretical sample contrast were found to be equal, 
which indicates homogeneity of the particles. For the core-shell nanoparticles HL-52 
a “virtual” sample contrast is given; the result is closer to PBCA, which underlines the  
larger amount of PBCA compared to perdeuterated polystyrene in the particle.
Table 8: Sample contrast determined by contrast
Nanoparticle Sample contrast
Monomer  S  / 1014m-2 X D2O  Device
HL-22 PS 1.36 ± 0.22 0.28 ± 0.04 YuMO
HL-31 PS 1.40 ± 0.24 0.28 ± 0.03 YuMO
HL-51 D8-PS 6.29 ± 0.57 0.99 ± 0.08 YuMO
HL-52 D8-PS/PBCA 2.54† 0.45† V4
2003/I-SA EPMA/MAA 1.47 ± 0.81 0.29 ± 0.11 YelSub
† An average is given of the D8-PS core and PBCA shell. Devices: “YuMO” - spectrometer YuMO, JINR, Dubna;  “V4” - spectro-
meter V4, BENSC, Berlin; “YelSub” - spectrometer “Yellow submarine”, BNC, Budapest. Monomers: PS - polystyrene, D8-PS - 
perdeuterated polystyrene, PBCA - poly(butyl cyanoacrylate), EPMA - 2,3-epoxypropylmethacrylate, MAA - methacrylic acid
3.3.3. Nanoparticle degradation
Core-shell  nanoparticles  were  degraded  using  porcine  liver  carboxylesterase.  To 
achieve stable enzyme activity the experiments were performed in 1:10 diluted HBSS 
buffer  avoid aggregation of particles or  degradation products.  After  adding of  the 
enzyme to the nanoparticle suspension, the reaction batch was filled in a neutron 
scattering cuvette and placed in the sample holder, which was heated to 37°C.
This enzyme exhibits a neutron scattering length density of about 1.9∙1014 m-2, which 
is  close to  the  value  for  poly(butyl  cyanoacrylate)  with  1.45∙1014 m-2.  Due to  the 
similar concentration of the nanoparticle and the enzyme (2 g/l), the scattering signal 
is superimposed by the enzyme. Therefore, the determination of particle radii may be 
distorted.
The  nanoparticle  type  HL-50  displayed  a  reduction  of  the  particle  radius  and 
decreasing scattering intensity (fig. 42). The radius of gyration felt from 28.5 nm to 
18.3 nm, for a spherical particle these radii equal 36.8 nm and 23.7 nm, respectively. 
The former is lower than 50.6 nm, determined for HL-50, while the latter is lower than 
the 38.6 nm of the polystyrene core HL-49. The scattering intensity was decreased 
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by 92%, the half life is estimated with 1.7 hours. Data were recorded in intervals of 
five minutes, hence, the measured intensities exhibit high variation. 
Degradation of nanoparticles HL-52 consisting of a perdeuterated polystyrene core 
and  a  PBCA shell  was  observed  with  two  different  solvent  contrasts.  When the 
solvent  matched  the  scattering  length  density  of  the  shell,  no  alteration  of  the 
scattering was observed (fig. 43), the determined radius of gyration of about 26 nm 
nearly equals the 23.6 nm of the core particle HL-51. Using a contrast that almost 
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Figure 42: Degradation of nanoparticles HL-50 monitored by small-angle neutron scattering: reduction 
of the nanoparticle radius (left) and scattering intensity (right).  HL-50 (polystyrene core and PBCA 
shell, 2 g/l) diluted in 1:10 HBSS buffer and porcine liver esterase (2 g/l) at 37°C. Measured at “Yellow 
submarine”, BNC, Budapest.
Figure  43:  Degradation  of  nanoparticles  HL-52  monitored  by  contrast  variation  and  small-angle 
neutron scattering:  reduction of  the nanoparticle  radius (left)  and  scattering intensity  (right)  if  the 
solvent nearly matches the core neutron scattering length density (X(D2O)=0.8, circles); unchanged 
particle radius and scattering intensity if the solvent matches the neutron scattering length density of 
the shell (X(D2O)=0.3, triangles). HL-52 (perdeuterated polystyrene core and PBCA shell, 2 g/l) diluted 
in 1:10 HBSS buffer and porcine liver esterase (2 g/l) at 37°C. Measured at “Yellow submarine”, BNC, 
Budapest.
matches the core (solvent 4.9∙1014 m-2, D8-PS 6.3∙1014 m-2) a clear degradation of the 
PBCA shell  was  observed;  the radius of  gyration  felt  from 22 nm to  15 nm.  The 
particle radius of HL-52 was measured with 76 nm; whereas, the scattering intensity 
decreased by 90% and the half-live was determined with 1.9 hours.
In an alternative approach the nanoparticles HL-52 with  a concentration of  10 g/l 
were degraded by porcine liver esterase (2 g/l) at 37°C in a 1:10 diluted HBSS buffer. 
At  certain  time points  an  aliquot  was  diluted  1+4 in  4°C cold  buffer  to  stop  the 
enzyme activity.  Subsequently,  the diluted samples were  measured at  4°C for  at 
least 1 hour; data were obtained for four different D2O contents (fig. 44).
Particle degradation was found in all  samples, but a complete degradation of the 
particle shell was not revealed. At the most, the gyration radius felt to 40 nm in the 
sample which matches the contrast of the core, about 16 nm larger than the radius of 
gyration of particle-core HL-51. Furthermore, the sample with an D2O content of 0.28 
did not match the shell contrast, proved by the large initial gyration radius of 52 nm, 
12 nm  more  than  HL-51.  A  “virtual”  particle  contrast  was  calculated,  where  the 
contrast of the shell equals the contrast of the core. It was revealed, that this “virtual” 
contrast increases with the degradation progress (fig. 45). This can be interpreted as 
a decreased amount of PBCA from the shell compared to the constant amount of 
perdeuterated polystyrene of the core.
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Figure  44:   Degradation  of  nanoparticles HL-52 
observed  with  different  solvent  contrasts; 
spectrometer V4, BENSC, Berlin
3.4. Fit models
Equation  59 can be solved analytically for both models. Besides the distribution of 
particle radii, the scattering vector q  displays a high variability. This is caused by a 
GAUSSIAN distributed wavelength of the incident beam and the dimensions of sample 
and detectors. The error of  q  is estimated as  GAUSSIAN distributed; the theoretical 
scattering intensity is calculated as a weighted average between  I q−⋅ q   and 
I q⋅ q   using  2 1  nodes. Due to the combined appearance of  q  and R  in 
the  numerator  of  equation  59 a  higher  variation  of  q  is  combined with  a  lower 
variation of  R  and  vice versa[219].  Results  were  obtained for  HL-22 (table 9)  and 
HL-31 (table 10), both nanoparticles were assumed to be homogeneous with  d=0  
and l=0 .
Table 9: Results from fitting model 1, nanoparticles HL-32, =3 ; measured at YuMO, JINR, Dubna
X D2O  0.0 0.1 0.5 0.8 0.95
 1 12 1 12 1 12 1 12 1 12
Radius R I  / nm 29.2 33.5 28.1 32.2 29.2 33.9 27.5 33.1 28.4 33.4
 RI  / nm 4.6 1.6 4.7 3.2 4.9 1.9 5.7 2.0 5.2 1.8
RG  from R I 25.9 26.3 25.3 26.5 26.2 26.8 26.2 26.2 26.1 26.4
RG  from Guinier plot 27.3 27.3 27.4 26.8 27.1
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Figure  45: Degradation of nanoparticles HL-52 using contrast variation. To obtain a “virtual” particle 
contrast, scattering intensity for the both samples with high D2O-content were multiplied with -1 (left) 
and the interceptions with the X-axis were determined (right). The data revealed an increasing portion 
of D8-polystyrene in the particle as a measure of shell degradation. Spectrometer V4, HMI, Berlin. 
Table 10: Results from fitting model 1, nanoparticles HL-31, =3 ; measured at YuMO, JINR, Dubna
X D2O  0.0 0.1 0.5 0.8 0.95
 1 12 1 12 1 12 1 12 1 12
Radius R I  / nm 34.7 39.4 35.4 39.3 34.1 39.0 33.4 38.4 33.6 38.9
 RI  / nm 4.8 0.3 4.2 0.5 5.0 0.4 5.2 0.6 5.0 0.6
RG  from R I 30.0 30.5 29.8 30.4 29.7 30.2 29.5 29.8 29.4 30.2
RG  from Guinier plot 31.4 31.6 31.3 30.4 31.1
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3.5. Animal experiments
3.5.1. Immunohistochemical detection of β-amyloid in mouse brain tissue
To prove the expression of β-amyloid in the applied APPSwe/PS1 mouse model, 
transgenic animals were tested. Both anti-β-amyloid antibodies, SA 720 and SA 721, 
revealed a typical pattern of a severe β-amyloidosis (fig. 46) within the whole brain 
tissue of the tested mice. The antibodies showed a high intensity of staining as well 
as a very low background. Furthermore, the cores of β-amyloid plaques exhibited 
stronger labeling than the peripheral deposits.
3.5.2. Histochemical detection of β-amyloid in mouse brain tissue
The use of the thioflavin T derivative BTA-2 was tested  in vitro.  The dye exhibits 
intensive staining of β-amyloid plaques, but also a high background (fig. 47).
76
Figure 46: Immunohistochemical detection of  β-amyloid in a 61 week-old female mouse 
(APPSwe/PS1A246E) using rabbit anti-β-amyloid SA 721, visualized with Cy3-goat-anti-
rabbit;  hippocampus (left),  neocortex (right).  Pictures were obtained by confocal laser-
scanning microscopy (Zeiss LSM 510 Meta). Scale bar 100 µm
BTA-2 is hardly soluble in 
water,  therefore,  DMSO 
and  ethanol  were  added 
to  increase  solubility. 
These solvents may inter-
fere  with  other  staining 
and  may  damage  nano-
particles.  Thus,  BTA-2 
was not further used.
3.5.3. Intracerebral application of free thioflavin dyes
After intrahippocampal injection of thioflavin T the dye was found distributed over the 
entire hemisphere. Thioflavin  T showed intensive labeling of  β-amyloid containing 
plaques and, a low but significant background labeling (fig. 48). 
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Figure  48:  Intrahippocampal  injection  of  thioflavin  T  in  a  60 week-old  female mouse 
(APPSwe/PS1A246E);  the  tissue  was  fixed  three  days  after  injection;  hippocampal 
region. Picture was obtained by a Axioplan fluorescence microscope combined with a 
camera, exposure time 220s, gamma corrected (γ=0.5). Scale bar 100 µm
Figure 47: Histochemical detection of Aβ in a 60 week-old female 
mouse (APPSwe/PS1A246E) by BTA-2. Scale bar 100 µm 
After  injection  of  thioflavin S  into  one  hemisphere  (ipsilateral  side),  the  labeling 
intensity in the other, contralateral, hemisphere was significantly diminished (fig. 49). 
Staining  with  the  antibody  SA 721  demonstrated  homogeneous  distribution  of 
β-amyloid. Furthermore, it was observed, that the signal of thioflavin S correlates with 
the signal of the Aβ-specific antibody (fig. 49). No vascular β-amyloid was found.
3.5.4. Intracerebroventricular application of nanoparticles
After  intracerebroventricular  injection  of  thioflavin S-filled  nanoparticles  (HL-29)  a 
diminished  staining  of  β-amyloid  plaques  was  observed  (fig. 50),  compared  to 
intrahippocampal application. Nevertheless, plaques were targeted by the released 
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Figure 49: Double fluorescence labeling of senile plaques in the hippocampus of an aged transgenic 
mouse (60 weeks, female, APPSwe/PS1A246E).  In vivo binding of thioflavin  S to fibrillar  β-amyloid 
three  days  after  intrahippocampal  dye  injection  combined  with  the  Aβ-immunolabeling.  Thioflavin 
staining in vivo (bottom). Indirect immunofluorescence labeling of β-amyloid deposits with rabbit anti-
Aβ and red fluorescent Cy3-conjugated goat anti-mouse IgG  (top). Contralateral  hemisphere (left); 
ipsilateral  side  (injection  site,  right).  Arrows  indicate  the  co-localization  of  thioflavin  S  and  Aβ 
immunoreactivity  in  selected  plaques.  Pictures  were  obtained  with  an  Axioplan  fluorescence 
microscope (Zeiss), gamma corrected (γ=0.5). Scale bar = 100 µm.
dye in APPSwe/PS1 mice. Double staining with Aβ-specific antibodies revealed the 
selective binding of thioflavin S to β-amyloid (fig. 50). While the antibody marked the 
entire plaque, thioflavin S was found to be restricted to the core of plaque.
After intracerebroventricular application of RB-FIX3-PBCA-TF nanoparticles, the red 
fluorescent  nanoparticle  cores  were  found  close  to  the  application  site.  These 
particles exhibit no green fluorescence or FRET signal which proves the degradation 
of the PBCA shell (fig. 51). The nanoparticles were transported within the cerebro-
spinal fluid and, therefore, found at the interface between tissue and fluid (fig. 52), 
but the particles are restricted to blood vessels and did not enter the tissue (fig. 53).
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Figure  50: Hippocampal  β-amyloid deposits in 53 week-old female mouse (APPSwe/PS1dE9) three 
days after intracerebroventricular injection of ThS-filled nanoparticles (HL-29). Thioflavin staining  in  
vivo (left). Immunofluorescence labeling of Aβ deposits with rabbit anti-Aβ (SA 721) and Cy5-tagged 
goat anti-rabbit IgG (color-coded in red, center), merge (right). Confocal laser-scanning microscopy 
with a Zeiss LSM Meta 510. Scale bar 50 µm.
Figure 51: Intracerebroventricular application of core-shell nanoparticles in a 41 week-old male wild-
type mouse; The green fluorescent shells are degraded (left). Undegradable, red fluorescent cores 
remain closely to the injection site (center); merge (right). Scale bar 250 µm
3.5.5. Intrahippocampal application of thioflavin-filled nanoparticles
After  intrahippocampal  injection  of  undegradable  nanoparticles,  the  particles 
remained close to the injection site (fig. 54). No labeling of plaques was observed. 
After injection of thioflavin S-filled nanoparticles HL-29, targeting of  β-amyloid could 
be detected (fig. 55).  For the labeling of Aβ the dye has to be released from the 
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Figure 52: Intracerebroventricular application of core-shell nanoparticles in a 41 week-old male wild-
type  mouse;  nanoparticles  are  transported  by  the  cerebrospinal  fluid;  lateral  ventricles  and  third 
ventricle (left); medial longitudinal fissure (center); fourth ventricle (right). Scale bar 500 µm
Figure 53: Nanoparticles are restricted to blood vessels after intracerebroventricular application in a 49 
week-old female wild-type mouse; blood vessels stained with  Solanum tuberosum  lectin (left);  red 
fluorescent nanoparticles (center); merge (right). Scale bar 250 µm
degradable nanoparticle. In one case the nanoparticles were found within neurons of 
the basal forebrain, possibly after their retrograde transport (fig. 54).
Thioflavin S was observed to bind β-pleated sheet structures in the core of matured 
plaques,  which  demonstrates  highly  ordered  aggregates.  The  surrounding  less 
aggregated β-amyloid molecules are stained clearly with  the specific antibody but 
less with thioflavin S (fig. 55). 
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Figure 54: Intrahippocampal injection of undegradable EPMA/MAA nanoparticles (HL-38) 
in a female mouse (56 weeks, APPSwe/PS1dE). Left: Nanoparticles remain close to the 
injection site in murine hippocampus, β-amyloid plaques were found unmarked; scale bar 
100 µm. Right: Nanoparticles transported within neurons are found in the basal forebrain.  
Scale bar 25 µm.
Figure  55:  Hippocampal  β-amyloid deposits in a 60 week-old female mouse (APPswe/PS1A246E) 
three  days  after  intrahippocampal  injection  of  thioflavin S-filled  nanoparticles  (HL-29).  Thioflavin 
staining in vivo (left). Immunofluorescence labeling of Aβ deposits based on rabbit anti-Aβ (SA 721) 
and Cy3-conjugated goat anti-rabbit IgG (center).  Merge (right). Note the restriction of the thioflavin 
staining  to  the  β-pleated  sheet  structures  in  the  core  of  the  plaque.  Confocal  laser-scanning 
microscopy with TCS SP2 AOBS (Leica). Scale bar 10 µm.
3.5.6. Intracerebral application and detection of nanoparticle 2003/I-SA/ApoE 
After  intrahippocampal  injection  of  2003/I-SA/ApoE  the  nanoparticle  could  be 
detected by its fluorescence or by histochemical methods using free biotin binding 
sides (fig. 56).  The particles showed a similar distribution within the brain like the 
core-shell nanoparticles after intracerebroventricular or intrahippocampal application.
3.5.7. Detection of thioflavin T by electron microscopy
After  intrahippocampal  injection  photoconverted  thioflavin T  was  found  binding  to 
β-amyloid containing plaques (fig. 57 and 58). Furthermore, remnants of thioflavin T 
containing nanoparticles were found within phagosomes of microglia (fig. 59).
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Figure  57:  Binding  of  photoconverted  thioflavin  to  a 
hippocampal  β-amyloid-containing  plaque.  Electron-
dense structures located close to the plaque are probably 
phagosomes. Scale bar = 1 µm.
Figure 56: Detection of streptavidin-coated nanoparticle 2003/I-SA/ApoE in murine hippo-
campus 24 hours after intra-hippocampal injection in a wild-type mouse. Direct detection 
of  the red fluorescent nanoparticle (left),  labeling with  Cy-5-streptavidin (center,  color-
coded in green), labeling with biotinylated horseradish peroxidase and nickel-enhanced 
DAB (right). Scale bar 50 µm. 
3.5.8. Intravenous application of nanoparticles
PBCA nanoparticles could not be found within brain after intravenous application also 
if coated with polysorbate 80. This applies for HL-23, HL-29, HL-32, HL-33, HL-50, 
HL-50T, RB-FIX2-PBCA-TF and RB-FIX2-PBCA-TF. No brain uptake were observed 
for  the  EPMA/MMA  nanoparticles  HL-34  –  HL-42  or  2003/I-SA.  Considerable 
amounts of all particles were seen in the liver of the injected mice and less in the 
spleen  (Fig. 60).  Negligible  numbers  of  particles  were  found  in  kidney  and  lung, 
whereas heart muscles were apparently devoid of particles (Fig. 60). High amounts 
of nanoparticles were detectable in blood after one hour but not after 24 hours (data 
not shown).
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Figure  58:  Photoconverted  thioflavin  bound  to  β-sheet 
structures  of  a  senile  plaque  with  an  electron-dense 
center.  The  periphery  of  the  plaque  allows  the 
identification  of  linear  arranged  amyloid  within  a 
completely disorganized neuropil. Scale bar = 1 µm.
Figure  59:  Hippocampal  microglia  displaying 
photoconverted  thioflavin  within  heavily  degenerated 
neuronal  tissue.  Several  photoconverted  phagosomes 
are apparent in the cell body. Note the nanoparticles in 
the vicinity of the cell, at higher magnification in the inset. 
Scale bar = 5 µm.
Nanoparticles coated with ApoE peptide were detected within brain tissue (Fig. 61). 
However, most of the particles were found in the liver of the treated animals.
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Figure 60: In-vivo distribution of nanoparticles 2000/I-SA/ApoE after intravenous application in a wild-
type mouse. Considerable amounts could be found in liver (top left) and spleen (bottom left), whereas 
no particles were found in kidneys (top right) and heart (bottom right). Scale bar: 50 µm
Figure  61: Nanoparticle 2003/I-SA/ApoE found in murine brain 3 days after intravenous application 
(wild-type mouse). Red fluorescent particles (left), within brain tissue (bottom). Scale bar 50 µm
3.6. Polymeric nanoparticles and blood coagulation
After intravenous application of the polymethacrylate nanoparticles HL-35 numerous 
cavities in the brain of two treated mice were observed (fig. 62). As a possible reason 
a stroke was suspected and, therefore, the activation of the coagulation system by 
polymeric nanoparticles was investigated.
PBCA nanoparticles displayed increased Endogenous thrombin potential as well as 
an increased thrombin peak compared to a reference sample (tab. 11, fig. 63). In 
addition, the lag phase and the time to peak is shortened. One polystyrene core was 
investigated  and revealed an  analogous result  but  only  marginal  increase of  the 
thrombin  peak.  For  the  polymethacrylate  nanoparticles  it  was  found  that  the 
Endogenous thrombin potential and thrombin peak were slightly diminished, the lag 
phase was shortended.
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Figure  62:  Necrotic  areas  within  murine  brain  after 
intravenous  application  of  polymethacrylate 
nanoparticles HL-35. Photography of the isolated brain 
mounted on a slide microtome. Note the  numerous 
cavities in both hemispheres. 
Table  11:  Thrombin generation in  platelet-rich  (PRP) and platelet-poor plasma (PPP) spiked with 
nanoparticles. PBCA nanoparticles HL-23,  HL-29, HL-32,  HL-33, FIX2 and FIX3; polystyrene core 
particle  HL-31  and  polymethacrylate  nanoparticles  HL-35  -  HL-38.  The  values  for  the  reference 
plasma are given with standard deviation.
The differences between  platelet-rich  and platelet-poor  plasma were  insignificant, 
only the lag phase in PPP was shorter applying polymethacrylate nanoparticles. 
The analysis of the platelet function using FACS revealed unchanged platelet activity 
and activatability for the PBCA nanoparticles HL-23, HL-29, HL-32 and HL-33 and a 
higher sensitivity to thrombin receptor activation (fig 64). The polystyrene core HL-31 
showed strong CD62P expression in unactivated platelets as well as after activation 
by ADP and TRAP-6. 
All  polymethacrylate  nanoparticles  displayed  increased  platelet  activity  and 
activatability.  These values may be interfered by the  fluorescence of  the particle 
itself.
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Figure 63: Relative changes in thrombin generation in platelet-rich (PRP, light gray) and platelet-poor 
plasma (PPP, dark gray) spiked with nanoparticles. PBCA nanoparticles HL-23, HL-29, HL-32, HL-33, 
FIX2 and FIX3; polystyrene core particle HL-31 and polymethacrylate nanoparticles HL-35 - HL-38. 
“SD” shows the standard deviation of the reference sample. 
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Figure  64: Determination of platelet function by P-selection (CD62P) expression, unactivated (dark 
gray), activated with ADP (gray) and TRAP-6 (light gray). PBCA nanoparticles HL-23, HL-29, HL-32, 
HL-33, FIX2 and FIX3; polystyrene core particle HL-31 and polymethacrylate nanoparticles HL-35 - 
HL-38.  
4. Discussion
4.1. Physical properties of polymeric nanoparticles
4.1.1. Absorbance spectra of polymeric nanoparticles
The measurement of light absorbance spectra revealed a superimposed signal of 
RAYLEIGH scattering and absorbance by particle components and dyes. Therefore, it is  
possible  to  estimate  particle  sizes  using  photometric  methods.  Nevertheless,  two 
different  values  determine  RAYLEIGH scattering,  the  radius  of  the  particle  and  its 
polarizability  . If one is known, the other one can be estimated [61]. Polysorbate 80-
coating  of  nanoparticles  with  encapsulated  thioflavin T  did  not  influence  the 
absorbance spectrum[62].
The  degradation  of  polymeric  nanoparticles  was  observed  using  absorbance 
measurement data. The reaction process was determined by the concentration of 
enzyme and the nanoparticles, e.g., the degradation was slowed be lower enzyme 
concentration  or  increased  nanoparticle  concentration.  Surface  coating  led  to 
decreased reaction velocity,  but  under  the used physiological  condition regarding 
temperature,  pH and salt  content,  the nanoparticles were  degraded within  hours. 
Changes  of  these reaction  conditions  influenced  the  degradation  process [61].  It  is 
noteworthy, that polymeric nanoparticles may swell when incubated in salt-containing 
solution,  a  process  that  must  be  considered  in  experiments [61].  To  ensure 
physiological conditions, all further experiments were performed in buffered solutions 
at a pH of 7.4.
In  summary,  analyzing  nanoparticle  size  and  degradation  by  absorbance 
measurements allows fast and practicable handling, high throughput and requires 
low technical effort. Two limitations must be considered, for  RAYLEIGH scattering the 
nanoparticle  diameter  must  be  smaller  than  the  wavelength;  aggregation  and 
sedimentation should be avoided. 
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4.1.2. Fluorescence spectra of polymeric nanoparticles
The  model  drugs  thioflavin T  and  thioflavin S  showed  strong  fluorescence  when 
encapsulated in polymeric nanoparticles. This allows the identification of particles in 
vitro and  in  vivo.  Nanoparticles  containing  two  fluorophores  showed  beside  the 
spectra of  the used dyes an additional  FÖRSTER resonance energy transfer-signal, 
which  enables  to  study  the  integrity  of  core-shell  nanoparticles.  In  vivo,  the 
fluorescence of the thioflavin-filled shell diminished and the FRET-signal diminished 
within three days, while the rhodamine B-signal of the the core was detectable close 
to the injection site.
In this work, it was not possible to investigate nanoparticle degradation in vitro, due 
to the lack of a multi-channel fluorescence spectrometer, equipped with the required 
wavelength filters and temperature regulation.
4.1.3. Static and dynamic light scattering
Both static  and dynamic  light  scattering  allowed  to  determine particle  radius  and 
radius distribution. The radii of the investigated nanoparticle core laid between 33 
and 40 nm. Core-shell nanoparticles displayed values between 50 and 72 nm when 
measured by static light scattering and subsequent analysis in a  GUINIER plot. This 
technique bases on the acquisition of scattering intensity data using different particle  
concentrations and scattering angles. It is noteworthy, that higher concentrations of 
nanoparticle suspensions may induce multiple scattering processes, which negatively 
influence the analysis.
Dynamic  light  scattering  bases  on  the  diffusion  of  nanoparticles  in  the  selected 
solvent and is determined by the hydrodynamic radius of the particles. This may also 
include  water  molecules  that  were  bound  to  the  particle  by  its  surface  charges. 
Therefore, hydrodynamic radii may be larger than the radius of the particle itself. For 
the polystyrene core HL-22 a hydrodynamic radius of  35.6  ± 0.5 nm was revealed, 
compared to 33.8 ± 1.8 nm from static light scattering. The radii for HL-31 were found 
to be nearly identical,40.8 ± 0.3 nm and 40.0 ± 0.5 nm, respectively.  Polystyrene 
nanoparticle  surfaces  contain  negatively  charged  sulfate  groups  from  the 
polymerization  process,  which  may  lead  to  a  solvation  layer.  For  the  PBCA 
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nanoparticles HL-23 the hydrodynamic radius was found to be slightly smaller than 
the radius based on static light scattering data, 67.5 ± 2.8 nm compared to 72.2 nm. 
Coating of PBCA nanoparticles with polysorbate 80 could be detected with a gain of 
about 0.5 nm. Red fluorescent nanoparticles could not be investigated due to strong 
absorption of the incident light and their strong fluorescence that interferes with the 
scattered light. Furthermore, fluorescent dyes are bleached by the intense laser light, 
therefore, the interference with light scattering changes during measurement.  
The  determination  of  nanoparticle  degradation  by  light  scattering  failed  due 
aggregation  of  particles,  degradation  intermediates  or  core  particles.  It  could  be 
shown,  that  neutralization  of  the  negatively  charged  surface  of  polystyrene 
nanoparticles led to aggregation.
Light scattering requires a high technical effort, additionally, static light scattering is 
time  consuming.  Nevertheless,  this  technique  is  nearly  unrivaled  for  radius 
determination. Alternative techniques like atomic force microscopy can not be used 
with  polymeric  nanoparticles  that  tend  to  aggregation  and  must  be  solved  in  a 
aqueous solution.
4.1.4. Small angle neutron scattering
The second technique to investigate nanoparticle radius and degradation was small 
angle neutron scattering. Radius determination using the GUINIER law revealed values 
comparable to  light scattering. For  HL-22 the radius of  gyration was found to  be 
27.3 nm,  with  static  light  scattering  25.9 nm,  for  HL-31  the  value  was  31.4 nm 
compared to 31.0 nm, respectively.  The variation of the solvent neutron scattering 
contrast had no influence on the radius determination, if the solvent did not match the  
particles scattering contrast. If the latter occurs, the extinguished scattering intensity 
precludes any data. On the other hand, using different  solvent  contrasts allow to  
investigate  nanoparticle  cores  or  shells  independently  from  each  other.  This 
approach  was  used  in  degradation  experiments,  showing  that  the  shell  of  the 
nanoparticle was clearly degraded, whereas the core remained unchanged. 
The  particle  degradation  was  performed  under  conditions  comparable  to  the 
experiments  using  photometry.  Half-life  of  shell  degradation  revealed  by  both 
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experiments was comparable despite the used of different detection techniques. For 
HL-50 the scattering intensity decreased more than 90% with a half-life of 1.7 hours, 
compared to 1.8 hours shown by photometry. The degradation of the HL-52 shell led 
to a 90% reduction of the scattering intensity with a half-life of 1.9 hours. Due to the 
high concentration of porcine liver esterase the scattering signal may be influenced 
by the enzyme causing an insufficient determination of nanoparticle radii using the 
GUINIER law. Furthermore, the short measurement interval led to data with low statistic 
quality.
In a second approach the degradation was performed outside the instrument and 
with  higher  particle  concentrations.  Prior  the  measurement,  samples  were  highly 
diluted  in  cold  solvent  which  stops  the  enzymatic  reaction.  Measurements  were 
carried  out  with  longer  data  acquisition,  which  led  to  data  with  higher  statistical 
quality and lower influence of the enzyme. In this experiment, the shell of the used 
HL-52  nanoparticle  was  not  degraded  completely.  An  explanation  may  be  the 
relatively low concentration of the enzyme. Furthermore, the enzyme did not degrade 
the polycyanoacrylate backbone of the polymer. These molecules may form random 
coils  or  stay bound to  the nanoparticle  core;  in  both cases the molecules led to 
isotropic scattering. A further reduction of the enzyme concentration or applying an 
enzyme  with  higher  activity  may  be  helpful  to  improve  data  quality  in  further 
experiments.
A further advantage of contrast variation is the determination of the particle neutron 
scattering contrast. It could be show, that all particles exhibited contrast comparable 
to  the  predicted  values.  This  underlines  that  the  investigated  nanoparticles  are 
homogeneous and, therefore, do not include solvent from fabrication.
Two fit models were used to interpret neutron scattering data. The results of fitting 
revealed high accordance to the data obtained by the GUINIER law. On the other hand, 
in  both  models  the  minimalization  parameter  is  dominated  by  the  intensities 
determined by for low q -values, which are used in the GUINIER law. The determination 
of radius distribution is influenced by the estimation of the error of q . If the data are 
calculated with a higher number of nodes for the distribution of q  then a lower radius 
distribution was achieved.
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Model  1  is  useful  for  fitting  data  from homogeneous  nanoparticles.  Because  the 
radius distribution of the core and the shell is constricted to the same value, fitting 
fails for core-shell nanoparticles, where the core radius distribution is usually smaller 
than the shell radius distribution. This applies especially for nanoparticles consisting 
of polymers  with  different  scattering length densities like HL-52.  On the contrary, 
HL-50 can be assumed as homogeneous particles, the contrast of core and shell 
differ with less than 5%. Model 2 consists of seven different parameters to be fitted in 
analysis. Therefore, it is impossible to fit data with reproducible results. Nevertheless, 
this model can be used if core or shell data are known and do not need to be fitted.  
Furthermore,  it  is  possible  to  fit  samples  with  different  solvent  contrast 
simultaneously. Both models can only be used, when the obtained data display good 
statistics.
Small  angle  neutron  scattering  is  a  method  with  extremely  high  technical  and 
analytical effort. The feasibility of contrast variation allows to investigate the structure 
of  polymeric  nanoparticles.  The  postulated  enzymatic  degradation  of  polymeric 
nanoparticles could be verified using small angle neutron scattering. The reduction of  
scattering intensity is a direct measure of the degradation process.
4.2. Detection and targeting of β-amyloid in transgenic mice
The transgenic mice used in this work showed a severe β-amyloidosis in the brain of 
the APPSwe/PS1 as well  as the APPSwe/PS1dE9 strain.  Despite a high general 
β-amyloid load no vascular deposits were found. Plaques were detected using the 
antibodies SA 720 and SA 721 which bind to human Aβ1-40, Aβ1-42 and Aβ1-43[234]. The 
high specificity of the performed indirect immunofluorescence labeling allows a good 
detection  of  β-amyloid  with  a  low  background  signal.  Furthermore,  SA 720  and 
SA 721 enable  Aβ detection without formic acid pretreatment which would interfere 
with the preceding thioflavin binding of fibrillar plaques in vivo. 
The  dyes  thioflavin  T  and  thioflavin  S  revealed  a  similar  distribution  pattern of 
plaques. On the other hand, concomitant thioflavin staining and Aβ immunolabeling 
showed slight differences; the thioflavins could only found in the core of the plaques, 
whereas  the  antibody  revealed  β-amyloid  also  in  the  surrounding  area.  These 
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findings are in accordance with  the fact that thioflavins bind to highly aggregated 
fibrils, which are formed in the center of the plaque, but not bind to diffusely occurring 
Aβ[145][146][142].  After intrahippocampal application of the free dyes strong labeling of 
β-amyloid was found, whereas thioflavin T showed a low but significant background. 
The labeling of Aβ diminished with the distance from the injection site, especially the 
contralateral hemisphere showed an lower signal. Both dyes are known to be unable 
to pass the blood-brain barrier[146] and are, therefore, appropriate model drugs for the 
investigation of brain targeting.
The uncharged thioflavin derivative BTA-2 is able to pass the blood-brain barrier [146] 
and was considered as a possible positive control in animal experiments. However 
the high background of the labeling which may be mediated by its hydrophobicity and 
its low solubility in water led to the exclusion from further experiments. Solutions of  
BTA-2 which were used in the experiments contained larger amounts of dimethyl 
sulfoxide  and  alcohols,  and  both  solvents  may  influence  the  permeability  of  the 
blood-brain barrier[166][159].
4.2.1. Intracerebral application of polymeric nanoparticles
To  prove  distribution  and  degradation  the  polymeric  nanoparticles  were  injected 
directly  into  the  brain.  After  intracerebroventricular  application  the  particles  were 
found  distributed  within  the  cerebrospinal  fluid  but  not  within  the  brain  tissue. 
Nevertheless, staining of β-amyloid plaques by thioflavins released from degradable 
PBCA nanoparticles was observed. The specificity of the staining was confirmed by 
subsequent immunolabeling  in vitro. Similarly,  after  intracerebroventricular injection 
an in vivo labeling of β-amyloid was observed with a fluorescent acetylcholinesterase 
inhibitor released from nanoparticles[235].
After intrahippocampal application the nanoparticles were found predominantly close 
to the injection site. Diffusion of the particles was more restricted within brain tissue 
compared to the free dyes. Restricted diffusion is a finding described earlier in aged 
mice with severe amyloidosis[236], but also the particle size and surface charges have 
to be considered. Fluorescent PMAA/MAA nanoparticles were observed close to the 
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injection site but no labeling of β-amyloid plaques was observed; this underlines the 
stability of the methacrylate nanoparticles.
In contrast, thioflavins released from PBCA nanoparticles targeted β-amyloid after 
intrahippocampal injection but with lower intenity compared to the free dye. Three 
days  after  application,  the  double-fluorescent  RB-FIX3-TF-PBCA  particles  were 
found exhibiting the red fluorescence of the core but neither green fluorescence of 
the shell nor a FRET signal. Both findings support the methodical approach chosen 
in this work: after penetration of the blood-brain barrier, in this case physically, the 
nanoparticle  shell  was  degraded,  the  dye  or  drug  was  released  and  the  cores 
remained at the site of degradation.
The nanoparticle 2003/I-SA could be detected by fluorescence labeling as well as by 
biotinylated horseradish peroxidase and subsequent staining with nickel-enhanced 
diaminobenzidine. The streptavidin bound on the particle surface can be used for 
coupling a signal peptide for the targeting of organs, tissues or cells, for the coupling 
of drugs or diagnostic agents and for the detection of the particle itself.
After photoconversion of the fluorescent dye, electron microscopy was used to detect 
the dye and nanoparticles in brain tissue of treated mice. Nanoparticles were found in 
phagosomes, a cellular structure responsible for digestion of particular substances. 
Furthermore, electron dense β-amyloid plaques were found. Electron microscopy can 
be applied to detect nanoparticles also following their penetration through the blood-
brain barrier[55][233].
4.2.2. Intravenous application of nanoparticles
None  of  the  intravenously  injected  nanoparticles  entered  the  brain,  if  the  ApoE 
peptide was not coupled to the particle surface. Most of the particles were found in  
the liver,  less in spleen, only a few in lung or kidney,  whereas no particles were 
detected in the heart. The accumulation of particles in the liver can be explained by 
its  function  for  detoxification,  whereas  the  spleen  plays  an  important  role  in  the 
cellular immunity.
The uptake into the brain was observed using nanoparticles 2003/I-SA/ApoE which 
exhibit  an ApoE signal peptide at their surface. It  was described that coating with 
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polysorbate 80, as realized in HL-50T, leads to the binding of ApoE to the particle 
surface and mediates brain uptake via the LDL receptor[12][117]. Nevertheless, HL-50T 
was  not  able  to  pass  the  blood-brain  barrier.  This  might  be  explained  by  a  low 
efficiency of ApoE binding, since the surface charge density determines the protein 
adsorption  on  polymeric  nanoparticles  as  shown  previously  by  two-dimensional 
electrophoresis[237].  Liposomes  coated  with  an  apolipoprotein  peptide  fragment 
considerably improved their internalization by endothelial cells in vitro[119]. Therefore, 
biotinylated  ApoE  peptide  were  bound  to  the  particle  by  streptavidin-biotin 
complexes. Despite increased targeting of the blood-brain barrier the majority of the 
particles were still found in liver and spleen. LDL metabolism is a function of the liver 
and, hence, LDL receptor-mediated uptake into the liver may be the major reason for 
that finding. As an alternative to artificial drug carriers natural transport systems exist,  
e.g., for hexoses, amino acids or monocarboxylic acids which might be useful for the 
transport of certain drugs through the blood-brain barrier [238]. In addition, endothelial 
cells of the BBB are predominantly equipped with receptors, e.g., for transferrin [239]. It 
might  be assumed that  nanoparticles with  surface-bound transferrin or  antibodies 
directed against the transferrin receptor could be preferentially bound to endothelial  
cells of the blood-brain barrier and facilitate the brain targeting of nanoparticles. A 
recently  published  study  suggests  that  a  combination  of  magnetic  nanoparticles, 
guided by an external magnetic field, and focused ultrasound to open the blood-brain 
barrier, synergistically delivers therapeutics to the brain[240]. 
It was not possible to quantify the particle load for an organ. A possible way would be 
the use of radiolabeled nanoparticles[241] or radiolabeled model drugs[242] which allow 
quantification by its radiation.
The mechanisms of the drug delivery into the brain remain to be further elucidated. 
Nanoparticles may be transported simultaneously to the diapedesis of lymphocytes 
through  endothelial  cells  of  the  blood-brain  barrier [243].  In  addition,  alcohols  like 
n-butanol  as  degradation  products  of  PBCA  and  surface  coating  tensides  like 
polysorbate 80 can partially disrupt the BBB [166][159]. It was shown that nanoparticle 
surface charges alter integrity and permeability of the blood-brain barrier [123]. 
Collectively, nanoparticles are promising drug carriers for charged, hydrophilic drugs 
with low tendency to penetrate the blood brain barrier after intravenous application. 
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4.3. Alteration of the blood coagulation system
The polymeric nanoparticles used in this work caused a significant alteration of blood 
coagulation. Two different effects were observed depending on the applied polymers.  
In a thrombin generation assay poly(butyl  cyanoacrylate) nanoparticles showed an 
increased  thrombin  peak  and  an  increased  Endogenous  thrombin  potential.  The 
former  reveals  the  velocity  of  thrombin  formation,  the  latter  the  total  amount  of  
thrombin that  was  generated.  Furthermore,  the lag  phase,  the time until  the first 
generation of thrombin, is slightly diminished, while the time from the start  of  the 
reaction until the maximum velocity is clearly shortened. All these alterations indicate 
that PBCA nanoparticles activate the coagulation system and may catalyze thrombin 
generation  and,  therefore,  increase the  risk  of  thromboembolic  events [244][245].  The 
polystyrene core particle HL-32 displays a similar pattern but with lower intensity. 
Platelet  function  were  apparently  not  altered  by  the  particles  HL-23,  HL-29  and 
HL-33.  There is no explanation for the highly altered platelet function induced by 
HL-32; this finding is inconsistent with  the moderate particle-induced activation of 
thrombin generation.
The EPMA/MAA nanoparticles showed a different pattern of coagulation activation. 
Whereas generation of thrombin is unchanged, the lag phase is clearly shortened.  
This  result  is  supported  by  increased  activation  and  activatability  of  the  platelet 
function possibly resulting in a thrombophilic state. The data may explain the finding 
of necrotic areas within two murine brains after intravenous application of HL-35. 
Blood coagulation is catalyzed by components of the platelet surface, which lead to 
shorter lag phase and time to peak as well as higher thrombin peak and Endogenous 
thrombin potential[202].  Since the effects are measured in platelet-rich and platelet-
poor plasma, nanoparticles not only interact with platelets but also act like platelets.
On  the  other  hand,  these  results  may  be  helpful  in  the  development  of  platelet  
substitutes  for  patients  with  bleeding  complications  and  blood  loss.  Nano-  or 
microparticles  coated  with  components  of  the  coagulation  system  may  be  a 
therapeutic option in the treatment of live-threatening bleedings [206][207]. Furthermore, 
nanoparticles could serve as tool for targeting of platelets[205].
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5. Summary
The development  of  a  great  variety  of  nanoparticles  opened new approaches  in 
diagnosis and therapy of diseases. Nanoparticles act as carrier for drugs and control 
their stability, release and site of pharmacological action. This allows lower dosage, 
higher therapeutic impact and fewer side effects. Moreover, such carriers enable the 
application  of  insoluble  or  unstable  drugs,  which  are  not  applicable  as  free 
compounds. In this work, thioflavins, encapsulated in polymeric nanoparticles, were 
used as model drugs for the targeting of β-amyloid through the blood-brain barrier.
Several materials are used for the formulation of polymeric nanoparticles. Organic 
non-toxic degradable polymers like poly(butyl cyanoacrylate) are used to embed or 
adsorb drugs. The surface of nanoparticle can be modified to suppress or increase 
immunological reactions, the latter may be used for vaccination, or to bind agents 
that control the targeting by specific or unspecific interaction with tissues, cells or 
receptors.  Furthermore,  surface  modifications  and  the  high  surface-volume  ratio 
allow a controlled release of the transported drugs.
In this work two types of polymeric nanoparticles were investigated  regarding their  
ability to penetrate the blood-brain barrier. Core-shell nanoparticles were made from 
a polystyrene core and a shell of poly(butyl  cyanoacrylate). The particle shells are 
easily degradable by enzymes in the brain tissue. Homogeneous nanoparticles were 
made  of  poly(2,3-epoxypropylmethacrylate-co-methacrylic  acid)  and  are  hardly 
degradable as well as the core of the core-shell particles.
Various physical techniques were investigated for  in vitro analysis of nanoparticles. 
Such  methods  may  be  helpful  for  studying  drug  carriers  regarding  drug  load, 
degradation and drug release and, therefore, may help to accelerate development 
and reduce the number of animal experiments. For these experiments porcine liver 
esterase was used as a model enzyme for the degradation of the particles. 
In the present work it could be shown that polymeric nanoparticles exhibit  RAYLEIGH 
scattering properties, a linear relationship between absorbance and the inverse 4 th 
power  of  the  wavelength.  This  allows  to  estimate  the  particle  radius  which  is 
proportional  to  the  slope  of  this  relationship  by  a  rather  simple  method  like 
photometry. The absorbance signal is superimposed by the absorbance spectrum of 
embedded  substances  like  thioflavin T  and  the  polymer  itself.  Because  the 
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relationship between absorbance and wavelength remained linear also during in vitro 
degradation  experiments;  the  decreasing  particle  radius  can  be  observed  by 
diminished light absorbance. It is noteworthy, that RAYLEIGH scattering only applies for 
particles with a size clearly smaller than the wavelength of the light. 
Depending  on  its  shape  and  size  particles  scatter  light  in  an  angle-dependent 
manner;  this  property  is  used in  static  light  scattering experiments.  On the other 
hand, dynamic light scattering detects fluctuations of the scattered light induced by 
the BROWNIAN movement. The velocity of the movement is determined by a diffusion 
constant and is connected to the hydrodynamic radius of the particles by the EINSTEIN-
STOKES equation. Both methods are suitable for the determination of radii if the radius 
distribution is low and nanoparticle aggregates do not occur. It was not possible to 
monitor  enzymatic  nanoparticle  degradation  with  reliable  results  due  to  the 
occurrence  of  large  aggregates  caused  by  the  neutralization  of  the  negatively 
charged nanoparticle surface by ions of the buffered solution or released positively 
charged thioflavins. Further data are required to possibly avoid the aggregation of  
nanomaterials at the site of degradation.
While  light  scattering  techniques  are  restricted  to  the  surface  of  nanoparticles, 
neutrons  are  able  to  penetrate  soft  matter.  Small  angle  neutron  scattering  is 
dominated by the scattering of smaller atoms, especially hydrogen, which are present 
in organic polymers. In this work it could be shown, that this methodology is useful for  
the investigation of nanoparticle structure and degradation.
Small  angle  neutron  scattering  is  determined  by  the  neutron  scattering  contrast 
difference  between  the  sample  and  the  surrounding  solvent,  each  molecule  or 
polymer  exhibits  a  specific  contrast.  By the  variation  of  the  solvent  contrast,  the 
contrast  of  the  investigated  polymeric  nanoparticles  could  be  determined.  The 
measured  contrasts  were  identical  to  the  calculated  values  and,  therefore, 
homogeneous nanoparticles can be assumed.
The  degradation  of  nanoparticles  was  investigated  using  small  angle  neutron 
scattering. This method revealed, that the shell of core-shell particles was degraded 
in a time-dependent manner, the degradation led to reduction of scattering intensity 
of  about  90%,  the  half-live  was  comparable  to  experiments  performed with  light  
absorbance  measurements.  The  introduction  of  perdeuterated  polystyrene  cores, 
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with a highly different scattering contrast compared to PBCA, allows to observe that 
hardly degradable nanoparticle cores remained unchanged during degradation. 
Small  angle  neutron  scattering  is  useful  for  the  investigation  of  physico-chemical 
properties  of  polymeric  nanoparticles.  Beside  the  usual  use  for  particle  size 
determination it allows the quantification of particle degradation. 
One of the most challenging drug targets is the brain, which is separated from the 
blood stream by the blood-brain barrier. Nearly all substances are transported either 
selectively or actively to the brain, and possible toxic substances are removed or 
degraded  by  cells  within  the  blood-brain  barrier.  One  of  the  most  promising 
approaches to overcome this obstacle is to mask the drug or the drug carrier  to 
enable receptor-mediated uptake into the brain. It was concluded before, that drugs 
delivered by nanoparticles passed the blood-brain barrier, but  there is only indirect 
evidence, e.g., by measuring drug-induced diminished pain[12]. Until now the uptake 
and degradation of drug-loaded particles has not been shown directly by detecting 
them in brain tissue after intravenous application.   
Nanoparticles  investigated  in  the  present  study  contain  as  model  drugs  the 
fluorescent dyes thioflavin S or thioflavin T. Both green fluorescent dyes are known to 
bind  to  β-amyloid  fibrils,  the  major  component  of  plaques frequently  occurring  in 
Alzheimer's disease. As free dyes thioflavin S and thioflavin T are unable to penetrate 
the blood-brain barrier and are, therefore, useful model drugs. If the nanoparticles 
penetrate the blood-brain barrier, the shell will be degraded and dye molecules are 
released.  After  binding  to  β-amyloid  fibrils  thioflavin S  or  T  can  be  detected  by 
fluorescence  microscopy.  A  fluorescent  undegradable  core  may  remain  at  the 
injection site and is detectable simultaneously. 
To ensure to uptake of drug-loaded nanoparticles, an apolipoprotein E dipeptide was 
coupled  covalently  to  the  particle  surface  which  may result  in  receptor-mediated 
uptake. In this work, the uptake of polymeric nanoparticles into the brain was tested 
in transgenic mice with an age-dependent β-amyloidosis.
Various experiments were performed to investigate uptake, degradation and targeting 
of nanoparticles in vivo. Injection of the free model drug thioflavin T directly into the 
brain revealed strong labeling of β-amyloid plaques but also limited diffusion within 
the brain. Application of double-fluorescent nanoparticles, with a red fluorescent core 
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and  a  green  fluorescent  shell,  showed  complete  degradation  of  the  shell  and 
targeting of  plaques by thioflavin T, whereas the undegradable core remained at the 
injection  site.  After  intravenous  application  of  unmodified  nanoparticles  neither 
penetration of the blood-brain barrier was observed nor particles and labeled plaques 
were found in the brain. Most of nanoparticles were detected in the liver, responsible 
for  metabolism and  detoxification  and in  the  spleen,  showing involvement  of  the 
immune system. No or very few particles were found in heart, kidneys and lung. 
Penetration  of  the  blood-brain  barrier  was  only  observed  with  very  small 
nanoparticles with the apolipoprotein E dipeptide bound to the surface. Nevertheless, 
only few particles reached the brain, the majority was still found in liver and spleen.
In summary,  the present work describes various techniques for the elucidation of 
physico-chemical properties of polymeric nanoparticles in vitro  and in vivo.  It  was 
shown, that structure and degradation of nanoparticles could be monitored using light 
absorbance,  fluorescence  measurements,  light  and  neutron  scattering.  These 
methods  may  be  helpful  for  the  development  of  polymeric  drug-carriers. 
Simultaneously, these methods may reduce the number of animal experiments which 
are  needed  for  full  understanding  of  nanoparticle  properties  and  possible 
disadvantages.
Using animal experiments, it could be shown, that nanoparticles are able to reach the 
blood-brain barrier,  but still  with low efficiency. Further improvements, like surface 
modifications or alternative materials, may lead to new opportunities in diagnosis or 
therapy of diseases using this seminal drug carriers.
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Physical  and chemical  symbols  are  used without  further  explanation,  amino acid 
codes in accordance with IUPAC rules. This applies to abbreviations in common use 
too.
Aβ  β-Amyloid




APP Amyloid precursor protein
BBB Blood-brain barrier
BENSC Berlin Neutron Scattering Center
BNC Budapest Neutron Center, Hungary
BRR Budapest Research Reactor, see BNC
BSA Bovine serum albumin
BTA-2 4-(6-methyl-1,3-benzothiazol-3-ium-2-yl)-N,N-dimethylaniline
CD41 Platelet glycoprotein IIb of IIb/IIIa complex
CD62P P-selectin (also GMP-140)
DAB 3,3’- Diaminobenzidine tetrahydrochloride
DLS Dynamic light scattering
DMSO Dimethyl sulfoxide
DNA Deoxyribonucleic acid




FLNP Frank Laboratory of Neutron Physics, see JINR
FRET FÖRSTER resonance energy transfer
GMP-140 Granule membrane protein 140 (P-selectin, also CD62P)
HBSS Hank's Buffered Salt Solution
I
HEMA Hydroxyethylmethacrylate
HMI Hahn-Meitner-Institute, Berlin, Germany
IgG Immunoglobulin G
IgM Immunoglobulin M
JINR Joint Institute for Nuclear Research, Dubna, Russia









PLE Porcine liver (carboxyl)esterase (EC 3.1.1.1)
PPP Platelet-poor plasma
PRP Platelet-rich plasma
PSD Position sensitive detector
SANS Small angle neutron scattering
SLS Static light scattering









AVOGADRO constant N A  6.022⋅1023mol−1
BOLTZMANN constant k B 1.38065⋅10−23 JK−1







Elementary charge Qe  −1.602⋅10−19C
Neutron mass mn 1.6726⋅10−27kg
PLANCK constant h 6.6261⋅10−34 Js
III
7.3. Theoretical background for static light scattering
An  averaging  over  a  large  time  interval  collects  a  large  number  of  scattering 
processes.  Those are distributed symmetrically  around s=e ,  which  means,  that 
s=e x  occurs with the same certainty like s=e− x  and, therefore, ∣k e∣=∣k s∣=k .
The incident light is an electromagnetic wave E e  with a direction of polarization ne , 
amplitude of the electric field strength E0  and direction of propagation ke .
E e r , t =ne E0 e
i ker−t   (64)
In the location r  the incident field induces a time variable dipole moment d  r , t   
within  the  volume  element d V ,  which  is  proportional  to E e .  The  proportionality 
constant is the susceptibility  r  . 
d  r , t = r dV Ee r , t   (65)
The time variable dipole moment can be interpreted as HERTZIAN dipole and, therefore, 
itself emits electromagnetic radiation. The scattered field E i  as the far field of the 
HERTZIAN dipole is proportional to the second derivative with respect to time of the 
dipole moment at the retarded time tR [246]. Thus, the in the volume element d V  at 
the location r  scattered field exhibits at the detector at the location R=R⋅k s  and the 
time t  the electric field strength
d E s R ,r , t =




R  is  the  distance  between  sample  center  and  detector.  The  retarded  time tR  
represents the time tR  when the signal was emitted by the dipole, when the signal 








The third term of equation 64 accommodates, that the scattering volume has a finite 
dimension and, therefore, not all scatterers are within the origin. Every single atom 
within the sample is a dipole; the scattered field results from the interference of all  
those far fields. The resulting electric field strength in the direction of polarization ns  
in the detector is 
IV
ns E s R , t =∫
V


























d V ns r nee
iqr ei kR−t 
 
(68)
According to equation 13 the differential cross section 
d 
d   can be introduced. The 





2 c  (69)
The measured intensity at the detector with the sample-detector distance R  results 






c R2d   (70)











2c4 ∣ns∫V d V  r e
−iqr ne∣
2
≡〈∣F q∣2〉 , (71)
and the scattering amplitude of the sample can be written













dV  r  e−iqrne . (72)
Compared to equation 15 results the scattering amplitude of the molecule.





dV  r  e−iqrne  (73)





ns r ne  (74)
If  isotropic,  spherical  molecules are used,  the susceptibility  r   is  reduced to  a 
scalar  r  . This allows to derive an explicit form factor.
V
























dV ′d V ″ r ′ r ″ sin q r ′−r ″
q r ′−r ″
 (75)
Using the definition for the scattering function of a molecule P    






dV ′d V ″ r ′ r ″ sin q r ′−r ″
q r ′−r ″
, (76)
The form factor 〈∣ f i q ∣
2〉  equals 








2 P    (77)
i
2  is the scattering-effective polarizability of the molecule i , which is the difference 
between the polarizability of the molecule and the polarizability of the solvent. The 
used nanoparticles  can not  be  understood as  punctiform dipole;  therefore,  P    
represents  the  ratio  between  the  angular-dependent  scattering  intensity  of  a 
nanoparticle compared to punctiform scatterer with the same polarizability.
For  a  polymeric  nanoparticle,  consisting  of  repetitive  molecules  with  the  same 
averaged susceptibility  i≡i /V i , P    can be written as 






dV ′d V ″
sinq r ′−r″




























dV ′d V ″q r ′−r ″2  (79)
This  is  a  special  case  of  equation 26.  For  homogeneous particles  the  scattering 
length density is position-independent and can be isolated from the integral. Now the 




eiq Ri−R j 〉=N mol 1−2 A2M cO c2   (80)
VI
M  is the molecular mass and c  the mass concentration of the particle, A2  is called 
second  virial  coefficient  and  represents  interaction  of  nanoparticles  with  a  finite 









2P  ⋅N mol 1−2 A2M cO c2  . (81)
The polarizability  difference   is  a  molecular  measure  and,  therefore,  difficult  to 
access.  Using  the  CLAUSIUS-MOSOTTI equation   can  be  expressed  by  the 







nD  is the refractive index of the dilution, whereas nS  is the refractive index of the 
solvent.   p  represents the particle density N mol /V . With nD−nS≈d nD /dc ⋅c  and 
nDnS≈2nS  the polarizability results in 
i=
2 0nS c
p d nDd c  . (83)









p d nDd c 
2
P  ⋅V 1−2 A2M cO c2  . (84)









Furthermore, all constants or measures that are determined by the experiment are 





4 d nDd c 
2
 (86)
With =c N A/M  the RAYLEIGH ratio R  can be written as 
R=KcMP ⋅1−2A2Mc  . (87)






MP  12A 2Mc =
1
P  1M 2A 2 c  (88)
This equation is used to interpret data from static light scattering experiment in a 
GUINIER plot. 
VII
7.4. Theoretical background for dynamic light scattering
Due to the motion of the scatterers the DOPPLER effect causes wavelength shifts in the 
emitted light. This effect is small; therefore, dynamic light scattering is also called 
quasielastic  light  scattering  with ke =k s .  The  fluctuations  are  interpreted  as  time-
dependent variability of the susceptibility. With respect to all particle motions within 
the scattering volume equation 68 is written 






dV  r t e−iqr t ne . (89)
Translations  within  the  sample  determine  the  phase  factor e−iq Ri t  ,  whereas 
intramolecular vibrations influence e−iqr  t . Hence, different phenomena lead to the 
time-dependent fluctuations of the scattered field and, thereby, intensity fluctuations 
observed at the detector. On the other hand, the characteristic times for translations, 
rotations and vibrations are distinguishably different.
To  interpret  the  interference  pattern  observed  at  the  detector,  the  correlator 
calculates a normed intensity autocorrelation function g2   .
g2  ≡
〈 I st  I st〉t
〈 I st 〉t
2  (90)
In  dynamic  light  scattering   is  named  correlation  time.  I s  equals  the  squared 
magnitude of E s : I s=∣E s∣






At d t . (91)





〈 I st 
2〉t
〈 I st 〉t
2 lim
∞
g 2=1  (92)
Furthermore, a normed field autocorrelation function g1  is introduced. 
g2  ≡
〈E s t E st〉t
〈∣E s t ∣
2〉t
=
〈E s t E st〉t
〈I st 〉t
 (93)











Intensity autocorrelation function g2    and the field autocorrelation function g1  




This applies only under GAUSSIAN scattering[248].
g1  can be written as superposition of relaxant exponential functions e
−
R  with the 






R dR  (96)
g1  is a LAPLACE transformation of AR . Data are given only on a discrete time 





 j  (97)




In case of spherical particles the STOKES-EINSTEIN relation applies, giving a connection 








k BT  ns
2
 2
sin 2 12  . (100)
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Referat:
Polymere  Nanopartikel  sind  ein  vielversprechender  Ansatz  für  die  Diagnose  und 
Therapie von Krankheiten. Sie ermöglichen den Einsatz von schwerlöslichen oder 
instabilen Wirkstoffen. Ein weiterer Vorteil ist die Möglichkeit das Targetings, durch 
gezielte Modifikationen des Nanopartikels wird der Wirkstoff zum Zielort transportiert 
und kann dort  in der gewünschten Form freigesetzt werden; dadurch könnten bei 
erhöhter Wirksamkeit die Nebenwirkungen von Medikamenten reduziert werden.
Ziel  dieser  Arbeit  war  die  Untersuchung  von  physikalischen  und  biochemischen 
Eigenschaften von Nanopartikeln  bestehend aus einem abbaustabilen Polystyren-
Kern und einer biologisch abbaubaren Schale aus Polybutylcyanoacrylat. Es werden 
Methoden beschrieben, um die Größe, Struktur und den Abbau dieser Wirkstoffträger 
zu  untersuchen.  Die  untersuchten  Nanopartikel  zeigen  RAYLEIGH-Streuung,  sowohl 
Größe als auch Abbau können durch Messung des Absorptionsspektrums bestimmt 
werden.  Weiterhin  konnten  diese  Eigenschaften  mit  Hilfe  von  dynamischer  und 
statischer Lichtstreuung sowie Neutronenkleinwinkelstreuung untersucht werden. Bei 
letzterer  Methode konnte  gezeigt  werden,  dass die  Schale  größtenteils  abgebaut 
werden kann, während der Kern intakt bleibt.
In  einem weiteren Teil  der  Arbeit  wurde die  Überwindung der  Blut-Hirn-Schranke 
durch  polymere  Nanopartikel  untersucht.  Dabei  wurde  der  fluoreszierende 
Thioflavine als Modellwirkstoffe eingesetzt. Das Durchdringen der Blut-Hirn-Schranke 
konnte  nur  mit  Nanopartikeln  erreicht  werden,  an  deren  Oberfläche  ein  Apolipo-
protein E-Peptid  gekoppelt  war.  Es konnte  gezeigt  werden,  das die  Nanopartikel-
schale im Gehirn abgebaut wird,  der Wirkstoff  freigesetzt wird und an Amyloid  β, 
einem Marker der Alzheimer-Krankheit, bindet.
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